Cancer Research and Treatment

Original Articles

Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+ISH+ and HER2 3+ in HER2-Positive Breast Cancer: Lingjun Ma, Ran Zheng, Lingyun Xu, Ying Zhu, Hong Yin, Xiaoqing Zhang, Rong Deng, Jue Wang, Xiaoming Zha; Received December 12, 2024 Accepted April 18, 2025 Published online April 21, 2025; DOI: https://doi.org/10.4143/crt.2024.1200 [Accepted]

Abstract PDF: Purpose
Dual anti-HER2 drugs has become the standard regimen for neoadjuvant systematic treatment (NST) to HER2-positive breast cancer patients. However, the efficacy varies greatly among patients with different HER2 protein expression levels
Materials and Methods
A total of 575 HER2-positive breast cancer patients from multiple centers throughout China from 2013 to 2022 were retrospectively analyzed. We compared clinicopathological features in different HER2 IHC classes (HER2 2+ISH+ or HER2 3+), and their difference in response to NST and survival with single or dual anti-HER2 drugs. Drug sensitivity assays were used to evaluate different efficacy of anti-HER2 drugs in vitro.
Results
Compared to HER2 3+ subgroup, the HER2 2+ISH+ group had a higher proportion of HR+ status (48.7% vs. 76.1%; p < 0.001), more HER2 protein loss after NST, lower pCR rate (46.07% vs. 16.24%; p < 0.001), and tended to have worse DFS. In HER2 2+ISH+ patients, treated with pertuzumab and trastuzumab in combination had no significant improvement in pCR (19.12% vs. 12.24%; p=0.287) and DFS (p=0.908) than using alone. Drug sensitivity assay showed poor efficacy with dual anti-HER2 drugs in HER2 2+ISH+ cell lines, however, T-Dxd drugs had a satisfactory effect.
Conclusion
Owing to the differences in clinicopathological features and treatment efficacy, we considered the HER2 2+ISH+ group to be a distinct subtype and defined it as the HER2-moderate-positive (HER2-mod) subgroup. In this subgroup, dual anti-HER2 drugs did not exert significant improvement in pCR and DFS. Therefore, treatment optimization is warranted, with ADC drugs as potential options.

262 View
38 Download

Head and Neck Cancer

Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area: Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun; Cancer Res Treat. 2021;53(3):657-670. Published online December 7, 2020; DOI: https://doi.org/10.4143/crt.2020.899

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to develop web-based nomograms to precisely predict survival outcomes in patients with non-metastatic nasopharyngeal carcinoma (NPC) in an endemic area.
Materials and Methods
A total of 10,126 patients who underwent radical intensity-modulated radiotherapy at Sun Yat-sen University Cancer Center (SYSUCC) from 2009 to 2015 were analyzed. We assigned patients into a training cohort (SYSUCC-A, n=6,751) and an internal validation cohort (SYSUCC-B, n=3,375) based on computer-generated random numbers. Patients collected from Wuzhou Red Cross Hospital (WZRCH) between 2012 and 2015 were used as the independent external validation cohort (WZRCH, n=450). Concordance index (C-index) was used to determine predictive accuracy and discriminative ability for the nomogram. The web-based clinicopathologic prediction models for predicting survival were based on Cox regression.
Results
The C-indexes for SYSUCC-A, SYSUCC-B, and WZRCH cohorts for the established nomograms to predict 3-year overall survival (OS) was 0.736, 0.715, and 0.691. Additionally, C-indexes to predict 3-year distant metastasis-free survival (DMFS) was 0.717, 0.706, and 0.686, disease-free survival (DFS) was 0.713, 0.697, and 0.656, local relapse-free survival was 0.695, 0.684, and 0.652, and regional relapse-free survival was 0.672, 0.650, and 0.616. The calibration plots showed great agreement between nomogram-predicted 3-year survival outcomes and actual 3-year survival outcomes. Moreover, C-indexes of the nomograms for OS, DMFS, and DFS were significantly superior than TNM stage (p< 0.001 for all).
Conclusion
These user-friendly nomograms can precisely predict survival endpoints in patients with non-metastatic NPC. They may serve as a useful tool for providing patient counseling and help physicians to make individual follow-up plans.

Citations

Citations to this article as recorded by

Adverse prognosis of nasopharyngeal carcinoma following long-term exposure to multiple air pollutants
Xiao Lin, Yanan Jin, Jijin Yao, Xurui Sun, Tian Tian, Zhiqiang Li, Shimin Chen, Jie Jiang, Weihua Hu, Yuantao Hao, Liangping Xia, Wangjian Zhang
Environmental Chemistry Letters.2024; 22(1): 21. CrossRef
The development and external validation of a web-based nomogram for predicting overall survival with Ewing sarcoma in children
Yi Chen, Zirui Liu, Yaobin Wang, Hongwei Zhan, Jinmin Liu, Yongkang Niu, Ao Yang, Fei Teng, Jinfeng Li, Bin Geng, Yayi Xia
Journal of Children's Orthopaedics.2024; 18(2): 236. CrossRef
The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis
Ya-Nan Jin, Meng-Yun Qiang, Ying Wang, Yu-Jing Lin, Ren-Wei Jiang, Wan-Wei Cao, Wang-Jian Zhang, Si-Yang Wang, Hong-Yu Zhang, Ji-Jin Yao
Cancer Immunology, Immunotherapy.2024;[Epub] CrossRef
Potential causal links of long‐term exposure to PM2.5 and its chemical components with the risk of nasopharyngeal carcinoma recurrence: A 10‐year cohort study in South China
Xurui Sun, Xiao Lin, Jijin Yao, Tian Tian, Zhiqiang Li, Shimin Chen, Weihua Hu, Jie Jiang, Hui Tang, Huanle Cai, Tong Guo, Xudan Chen, Zhibing Chen, Man Zhang, Yongqing Sun, Shao Lin, Yanji Qu, Xinlei Deng, Ziqiang Lin, Liangping Xia, Yanan Jin, Wangjian
International Journal of Cancer.2024; 155(9): 1558. CrossRef
ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA
Yanan Jin, Jijin Yao, Jianchang Fu, Qitao Huang, Yilin Luo, Yafei You, Wangjian Zhang, Qian Zhong, Tianliang Xia, Liangping Xia
Cell Death & Disease.2024;[Epub] CrossRef
The continuous improvement of digital assistance in the radiation oncologist’s work: from web-based nomograms to the adoption of large-language models (LLMs). A systematic review by the young group of the Italian association of radiotherapy and clinical o
Antonio Piras, Ilaria Morelli, Riccardo Ray Colciago, Luca Boldrini, Andrea D’Aviero, Francesca De Felice, Roberta Grassi, Giuseppe Carlo Iorio, Silvia Longo, Federico Mastroleo, Isacco Desideri, Viola Salvestrini
La radiologia medica.2024; 129(11): 1720. CrossRef
Selection of induction chemotherapy cycles for stage N3 nasopharyngeal carcinoma based on pre-treatment plasma EBV DNA
Youliang Weng, Sunqin Cai, Chao Li, Yun Xu, Yuhui Pan, Zongwei Huang, Ying Li, Zijie Wu, Yu Chen, Sufang Qiu
Scientific Reports.2024;[Epub] CrossRef
A Nomogram for Predicting Recurrence in Stage I Non‐Small Cell Lung Cancer
Rongrong Bian, Feng Zhao, Bo Peng, Jin Zhang, Qixing Mao, Lin Wang, Qiang Chen
The Clinical Respiratory Journal.2024;[Epub] CrossRef
Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response
Yu‐Ting Jiang, Kai‐Hua Chen, Zhong‐Guo Liang, Jie Yang, Song Qu, Ling Li, Xiao‐Dong Zhu
Cancer Medicine.2023; 12(4): 4010. CrossRef
The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy
Ji-Jin Yao, Ya-Nan Jin, Yu-Jing Lin, Wang-Jian Zhang, Tia Marks, Ian Ryan, Hong-Yu Zhang, Liang-Ping Xia
Radiotherapy and Oncology.2023; 178: 109414. CrossRef
Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors
Jianing Luo, Xiaonan Hu, Xiaofeng Ge
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10181. CrossRef
Construction of Prognostic Nomogram in Patients with N3-Stage Nasopharyngeal Carcinoma
Wenmiao Cao, Xiaoxin Li, Jianqi Yang, Enming Xing, Wenjuan Wu, Yizhi Ge, Buhai Wang
ORL.2023; 85(4): 195. CrossRef
Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases
Jie Ma, Rong Zhao, Yu-Lan Wu, Yang Liu, Guan-Qiao Jin, Dan-Ke Su
Cancer Imaging.2023;[Epub] CrossRef
Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
Ya-Nan Jin, Hui-Jiao Cao, Xiao-Hua Gong, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
Journal of Cancer Research and Clinical Oncology.2022; 148(10): 2569. CrossRef
Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma
Ya-Nan Jin, Qian-Qiong Yang, Zi-Qian Li, Xue-Qing Ou, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
Radiotherapy and Oncology.2022; 166: 118. CrossRef
A predictive web-based nomogram for the early death of patients with lung adenocarcinoma and bone metastasis: a population-based study
Zhehong Li, Junqiang Wei, Haiying Cao, Mingze Song, Yafang Zhang, Yu Jin
Journal of International Medical Research.2021;[Epub] CrossRef
The Role of Pretreatment 18F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
Jijin Yao, Ying Wang, Yujing Lin, Yingying Yang, Jingjing Wan, Xiaohua Gong, Fanwei Zhang, Wangjian Zhang, Tia Marks, Siyang Wang, Hongjun Jin, Hong Shan
Drug Design, Development and Therapy.2021; Volume 15: 4157. CrossRef

6,262 View
163 Download
17 Web of Science
17 Crossref

Immunotherapy

The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients: Si-Qi Tang, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Lei Chen, Yuan Zhang, Ying Guo, Qing Liu, Ying Sun, Cheng Xu, Jun Ma; Cancer Res Treat. 2021;53(2):339-354. Published online November 6, 2020; DOI: https://doi.org/10.4143/crt.2020.790

Abstract PDF Supplementary Material PubReader ePub

Purpose
The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear.
Materials and Methods
Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.
Results
Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).
Conclusion
This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.

Citations

Citations to this article as recorded by

Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival
Osias Vieira de Oliveira Filho, Ivana Lameiras Gibbons, Yuri de Lima Medeiros, Thiago Bueno de Oliveira, Nathaniel Simon Treister, Fabio Abreu Alves
Oral Diseases.2025; 31(1): 278. CrossRef
Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite Instability-High Metastatic Colorectal Cancer
Annie Xiao, Xiaochen Li, Chongkai Wang, Marwan Fakih
Clinical Colorectal Cancer.2025; 24(1): 32. CrossRef
Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system
Naoto Okada, Tomoyuki Yanagi, Takaaki Sasaki, Miho Tamura, Masakazu Ozaki, Atsuyuki Saisyo, Takashi Kitahara
International Journal of Cancer.2025; 156(2): 293. CrossRef
A Case of Olmesartan-associated Gastritis Observed Over Time
Mizuho Fujisawa, Tetsuya Yoshizaki, Satoshi Urakami, Risa Ashizaki, Eri Nishikawa, Hiroshi Tanabe, Shinya Hoki, Ryosuke Ishida, Hitomi Hori, Chise Ueda, Hirofumi Abe, Madoka Takao, Yoshinori Morita, Takashi Toyonaga, Yuzo Kodama
Internal Medicine.2025;[Epub] CrossRef
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer
Cynthia X. Wei, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, Greg A. Durm
Clinical Lung Cancer.2025; 26(3): e154. CrossRef
The use of peripheral blood biomarkers for predicting the risk of immune-related adverse events in immune checkpoint inhibitor therapy
Louise E Duvall
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2025;[Epub] CrossRef
Developing alert thresholds and self-management advice for people receiving immune checkpoint inhibitors: a Multinational Association for Supportive Care in Cancer modified Delphi survey
Julia Lai-Kwon, Claudia Rutherford, Stephanie Best, Hope S. Rugo, Christina H. Ruhlmann, Michael Jefford
Supportive Care in Cancer.2025;[Epub] CrossRef
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer
Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob ter Heine, Michel M. van den Heuvel, Valesca P. Retèl
PharmacoEconomics - Open.2025; 9(3): 471. CrossRef
Clinical and economic impact of the advanced practice nurse in lung cancer patients receiving immunotherapy-based treatments: A quantitative study
Jorgina Serra-López, Clara Pujol-Besora, Sergio Martínez-Recio, Andrés Barba Joaquín, Mariona Riudavets Melià, Ivana Sullivan, Jordi Torralbas-Ortega, Gina Lladó-Jordan, Margarita Majem, Maria-Antonia Martínez-Momblan
European Journal of Oncology Nursing.2025; 74: 102809. CrossRef
Long-term immune related adverse events
Leo Plaçais, Olivier Lambotte
Current Opinion in Oncology.2025; 37(2): 142. CrossRef
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study
Jonas Paul Wiegmann, Tabea Fröhlich, Nora Möhn, Laura Duzzi, Emily Narten, Johanna Aurich, Janin Thomas, Lea Grote‐Levi, Susann Mahjoub, Dominik Berliner, Thomas Wirth, Heiko Golpon, Benjamin‐Alexander Bollmann, Imke Von Wasilewski, Ralf Gutzmer, Florian
Cancer Medicine.2025;[Epub] CrossRef
Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions
Lingxiang Ran, Rui Zhao, Yu Li, Benfan Lin, Zhen Yang, Yuanyin Teng, Jingyi Li, Shi Wang, Hsu Yi Liang, Guangmo Hu
AI Med.2025; 1(1): 1. CrossRef
Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Xingyu Wei, Fei Li, Dehua Liao
Frontiers in Pharmacology.2025;[Epub] CrossRef
Challenges and opportunities in single-domain antibody-based tumor immunotherapy
Xiaozhi Xi, Shasha Guo, Yuchao Gu, Xuekai Wang, Qiang Wang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(2): 189284. CrossRef
Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis
Qimei Fang, Yan Qian, Zhaolu Xie, Hongqiong Zhao, Yang Zheng, Di Li
Frontiers in Immunology.2025;[Epub] CrossRef
Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients
Badiaa Batlamous, Sihame Lkhoyaali, Loubna Omri, Magaly-Gwen-Farnely Nguema-Mipaka, Mohamed Khalis, Hanane Inrhaoun, Sarah Naciri, Ibrahim El Ghissassi, Hind Mrabti, Saber Boutayeb, Hassan Errihani
JCO Global Oncology.2025;[Epub] CrossRef
Late-onset bone granulomatous reaction of hand from immune checkpoint-inhibitors detected on FDG-PET/CT
Miki Nishimori, Kouki Togami, Noriko Nitta, Kana Miyatake, Hitomi Iwasa, Kosuke Nakaji, Kenta Ogi, Takayasu Izumi, Tomohiro Matsumoto, Rika Yoshimatsu, Tomoaki Yamanishi, Kazufumi Takamatsu, Shudai Muramatsu, Mayuko Yamamoto, Takuji Yamagami
Radiology Case Reports.2025; 20(5): 2338. CrossRef
Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1
Yusuke Miyajima, Takeshi Kawakami
Cancers.2025; 17(7): 1120. CrossRef
Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database
Huiping Zhang, Zhuo Zhou, Juan Wang, Shan Wang, Jie Ren, Ming Zhang, Mingyi Yang
Frontiers in Immunology.2025;[Epub] CrossRef
Autoimmune-related adverse events induced by immune checkpoint inhibitors
Yuanqiang Sun, Ziyang Zhang, Ke Jia, Hong Liu, Furen Zhang
Current Opinion in Immunology.2025; 94: 102556. CrossRef
Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami, Aya F. Ozaki
Cardio-Oncology.2025;[Epub] CrossRef
Three-year analysis of the Belgian multidisciplinary immunotoxicity (BITOX) board: organization, feasibility, and results
M. Verhaert, Y. Aydogan, S. Aspeslagh
ESMO Real World Data and Digital Oncology.2025; 8: 100147. CrossRef
Lung cancer with diabetes mellitus and polymyalgia rheumatica during long‑term nivolumab treatment: A case report
Makoto Nakao, Ayami Hirano, Masato Nakai, Syuntaro Hayashi, Mamiko Kuriyama, Norihisa Takeda, Hideki Muramatsu
Experimental and Therapeutic Medicine.2025; 29(6): 1. CrossRef
Immune checkpoint inhibitors: From friend to foe
Prem Rajak
Toxicology Reports.2025; 14: 102033. CrossRef
Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer
Yalong Qi, Hewei Ge, Xiaoying Sun, Yuhan Wei, Jingtong Zhai, Haili Qian, Hongnan Mo, Fei Ma
Journal of Autoimmunity.2025; 153: 103423. CrossRef
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma
Sarit E. Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B. Johnston, Alexey V. Danilov, Brenda W. Cooper, Aleksander Chudnovsky, Junyu Ding, Tao Long, Dina Stroopinsky, Deborah Berg, Lapo Alinari
Clinical Lymphoma Myeloma and Leukemia.2025;[Epub] CrossRef
Dynamic variations in peripheral blood indices and their association with efficacy and adverse reactions of pd- 1 inhibitor combined chemotherapy in patients with advanced gastric cancer
Rui Wang, Huihui Zeng, Mengting Shi, Yue Wu, Yang Liu, Tiantian Zhang
BMC Gastroenterology.2025;[Epub] CrossRef
Immune checkpoint inhibitor–related adverse events: Real-world experience from a single veterans’ affairs medical center
Samantha Benz, Katherine A Sherman, Constantin A Dasanu, Juliana Alvarez-Argote
Journal of Oncology Pharmacy Practice.2024; 30(4): 697. CrossRef
Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors
Kremena Petrova Trichkova, Franziska Görtler, Line Bjørge, Cornelia Schuster
Cancers.2024; 16(2): 250. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía,
Gastroenterología y Hepatología.2024; 47(4): 401. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandí
Revista Española de Enfermedades Digestivas.2024;[Epub] CrossRef
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis
Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock, Seunghwan Shin
BMC Cancer.2024;[Epub] CrossRef
A case of Stiff-person syndrome with muscle tonicity of the extremities and neck after use of Dulvalumab for lung adenocarcinoma
Takashi Inoue, Kei Oiwa, Kazuhiro Horiuchi
Rinsho Shinkeigaku.2024; 64(3): 176. CrossRef
Clinical and translational attributes of immune-related adverse events
Karijn P. M. Suijkerbuijk, Mick J. M. van Eijs, Femke van Wijk, Alexander M. M. Eggermont
Nature Cancer.2024; 5(4): 557. CrossRef
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach
Desirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, Fausto Omero, Enrica Maiorana, Mariacarmela Cavaleri, Elena Sapuppo, Vincenzo Cianci, Alessia Pugliese, Vito Racanelli, Giulia Maria Camerino, Carmelo Rodolico, Nicola Silvestris
Expert Opinion on Drug Safety.2024; 23(11): 1405. CrossRef
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation
Arielle Elkrief, Nicholas R. Waters, Natalie Smith, Angel Dai, John Slingerland, Nathan Aleynick, Binita Febles, Pooja Gogia, Nicholas D. Socci, Melissa Lumish, Paul A. Giardina, Jamie E. Chaft, Juliana Eng, Robert J. Motzer, Robin B. Mendelsohn, Kate A.
Cancer Immunology Research.2024; 12(3): 308. CrossRef
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía,
Gastroenterología y Hepatología (English Edition).2024; 47(4): 401. CrossRef
Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity
静宜任
Advances in Clinical Medicine.2024; 14(03): 284. CrossRef
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, David Balakirouchenane, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Marie-Claire Bretagne, Joe-Elie Salem, Xavier Declèves, Michel Vidal, Nora Kramkimel, Sarah Guegan, Selim Aractingi, Olivier Hui
British Journal of Cancer.2024; 130(11): 1866. CrossRef
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian S
Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Mon
Cancer Treatment Reviews.2024; 126: 102734. CrossRef
Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka
Kanzo.2024; 65(6): 268. CrossRef
Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka
Hepatology Research.2024; 54(8): 719. CrossRef
Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?
Mohamed Mahmoud El-Sayed, Julia Raffaella Bianco, YiJing Li, Zsolt Fabian
Cells.2024; 13(12): 1071. CrossRef
Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer
O Karhan, Y Sezgin, S Ileri, S Tunc
Nigerian Journal of Clinical Practice.2024; 27(6): 800. CrossRef
Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, T
Cancer Medicine.2024;[Epub] CrossRef
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds,
The Lancet Oncology.2024; 25(8): 1053. CrossRef
Selecting Immune Checkpoint Inhibitor Side Effects for Real-Time Monitoring in Routine Cancer Care: A Modified Delphi Study
Julia Lai-Kwon, Michael Jefford, Stephanie Best, Iris Zhang, Claudia Rutherford
JCO Oncology Practice.2024; 20(12): 1663. CrossRef
Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis
Stephanie van der Leij, Karijn P.M. Suijkerbuijk, Medard F.M. van den Broek, Gerlof D. Valk, Jan Willem Dankbaar, Hanneke M. van Santen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action
Antonio Malvaso, Pierpaolo Giglio, Luca Diamanti, Matteo Gastaldi, Elisa Vegezzi, Andrea Pace, Paola Bini, Enrico Marchioni
Brain Sciences.2024; 14(8): 764. CrossRef
Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy
Gerald J. Sun, Gustavo Arango-Argoty, Gary J. Doherty, Damian E. Bikiel, Dejan Pavlovic, Allen C. Chen, Ross A. Stewart, Zhongwu Lai, Etai Jacob
iScience.2024; 27(9): 110634. CrossRef
Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico, Jocelynn Colunga-Minutti, Rayansh Poojary, Sayan Alekseev, Anisha B. Patel, Yuanteng Jeff Li, Ajay Sheshadri, Monica E. Loghin, Karin Woodman, Ashley E. Aaroe, Sarah Hamidi, Priyanka Chandrasek
Frontiers in Immunology.2024;[Epub] CrossRef
Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors
Christopher J. Hoimes, Suzanne McGettigan, Lee Schwartzberg
The American Journal of Medicine.2024; 137(12): 1200. CrossRef
Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study
Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada
Journal of Pharmaceutical Health Care and Sciences.2024;[Epub] CrossRef
Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
Xuefeng Duan, Haoyang Zou, Jiazhen Yang, Shixian Liu, Tianmin Xu, Jianxun Ding
Journal of Controlled Release.2024; 375: 285. CrossRef
Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic review
Yoni Byron, Sonya Yegorova‐Lee, Martin Tio
Cancer Medicine.2024;[Epub] CrossRef
Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver
Luca Marzi, Andrea Mega, Chiara Turri, Stefano Gitto, Federica Ferro, Gilbert Spizzo
International Journal of Molecular Sciences.2024; 25(21): 11676. CrossRef
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy
Iris Teruel, Eva Castellà, Sabela Recalde, Gemma Viñas, Anna Petit, Macedonia Trigueros, Eva Martínez-Balibrea, Eudald Felip, Milana Bergamino, Adrià Bernat-Peguera, Beatriz Cirauqui, Vanesa Quiroga, Angelica Ferrando-Díez, Anna Pous, Assumpció López, Lai
International Journal of Molecular Sciences.2024; 25(22): 12241. CrossRef
Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
Brooke Kielkowski, Diana Mansour, Brooke Ebbert, Kelsea Seago, Sijin Wen, Hang Li, Christine Barrett
Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef
Safety of sequential immune checkpoint inhibitors after prior immune therapy
Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit, Brigitte Gil, Natalie Dal’Bo, Lewena Maher, Seanna Reilly Daves, Stephanie McDonald, Krishna S. Gunturu
Journal of Cancer Research and Clinical Oncology.2023; 149(6): 2375. CrossRef
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
Murielle N. Wahli, Stefanie Hayoz, Dennis Hoch, Christoph O. Ryser, Michèle Hoffmann, Amina Scherz, Birgit Schwacha-Eipper, Simon Häfliger, Julian Wampfler, Martin D. Berger, Urban Novak, Berna C. Özdemir
Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3847. CrossRef
Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, Ayako Furugen, Yoh Takekuma, Naofumi Shinagawa, Yasushi Shimizu, Hirotoshi Dosaka-Akita, Mitsuru Sugawara, Masaki Kobayashi
Journal of Cancer Research and Clinical Oncology.2023; 149(4): 1659. CrossRef
Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis
Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng
International Immunopharmacology.2023; 114: 109490. CrossRef
Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis
Su Jeong Song, Yun-Kyoung Song, Mihwa Jang, Eunjeong Shin, Sung Yun Suh, Yoon Sook Cho, Ju-Yeun Lee, Jung Mi Oh
Targeted Oncology.2023; 18(1): 147. CrossRef
Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis
Qian Guo, Jin Ning Zhao, Ting Liu, Jian Gao, Hui Guo, Jing Min Cheng
Frontiers in Pharmacology.2023;[Epub] CrossRef
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. K. Mok, Martin Reck, Gene G. Finley, Monika D. Kaul, Wei Yu, Nindhana Paranthaman, Ilze Bāra, Howard J. West
JAMA Oncology.2023; 9(4): 527. CrossRef
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment
Gaetano Maria Russo, Anna Russo, Fabrizio Urraro, Fabrizio Cioce, Luigi Gallo, Maria Paola Belfiore, Angelo Sangiovanni, Stefania Napolitano, Teresa Troiani, Pasquale Verolino, Antonello Sica, Gabriella Brancaccio, Giulia Briatico, Valerio Nardone, Alfons
Diagnostics.2023; 13(4): 793. CrossRef
Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
Juyue Zhou, Zhonghai Du, Jie Fu, Xiuxiu Yi
Frontiers in Immunology.2023;[Epub] CrossRef
Gastritis as an immunotherapy-related toxicity in the treatment of endometrial cancer: A case report
Nidhi Goel, Monica D. Levine, Laura M. Chambers, Christa I. Nagel
Gynecologic Oncology Reports.2023; 47: 101174. CrossRef
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner
Journal for ImmunoTherapy of Cancer.2023; 11(3): e006398. CrossRef
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients
Berna C. Özdemir, Cristina Espinosa da Silva, Dimitri Arangalage, Pierre Monney, Sabina A. Guler, Uyen Huynh-Do, Guido Stirnimann, Lucia Possamai, Roman Trepp, Robert Hoepner, Anke Salmen, Camille L. Gerard, Petr Hruz, Lisa Christ, Sacha I. Rothschild
Cancer Immunology, Immunotherapy.2023; 72(7): 1991. CrossRef
Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features
Julianna Martel, Hannah L. Hanania, Anisha B. Patel
Human Pathology.2023; 140: 144. CrossRef
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity
Catherine C. Fahey, Thomas J. Gracie, Douglas B. Johnson
Expert Review of Anticancer Therapy.2023; 23(7): 673. CrossRef
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
Rafael Morales-Barrera, Guillermo Villacampa, Natalia Vidal, Mariona Figols, Julia Giner, Teresa Bonfill, Cristina Suárez, Nely Díaz, Joaquín Mateo, Macarena González, Montserrat Domenech, Javier Puente, Joan Carles
Clinical and Translational Oncology.2023; 25(12): 3556. CrossRef
The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review
Julia Lai-Kwon, Jordan E. Cohen, Karolina Lisy, Claudia Rutherford, Afaf Girgis, Ethan Basch, Michael Jefford
JCO Clinical Cancer Informatics.2023;[Epub] CrossRef
Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, Hiroki Kubota, Yusuke Noda, Maria Aoki, Yoshinobu Moritoki, Satoshi Nozaki, Satoshi Kurokawa, At
International Journal of Urology.2023; 30(10): 866. CrossRef
Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy
Shu-Jung Hsu, Yen-Cheng Chao, Xia-Hui Lin, Hua-Hua Liu, Yang Zhang, Wei-Feng Hong, Mao-Pei Chen, Xin Xu, Lan Zhang, Zheng-Gang Ren, Shi-Suo Du, Rong-Xin Chen
Clinical and Experimental Immunology.2023; 212(3): 239. CrossRef
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Céleste Lebbé, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stéphane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen B
Journal of Clinical Oncology.2023; 41(23): 3917. CrossRef
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
Hyo Sook Han, Praveen Vikas, Ricardo L.B. Costa, Nusrat Jahan, Ammanuel Taye, Erica M. Stringer-Reasor
American Society of Clinical Oncology Educational Book.2023;[Epub] CrossRef
An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management
Yiyu Cheng, Fangmei Ling, Junrong Li, Yidong Chen, Mingyang Xu, Shuang Li, Liangru Zhu
Frontiers in Immunology.2023;[Epub] CrossRef
Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma
Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Tetsuya Tsuchida, Ai Yoshida, Takako Yamada, Akira Komoto
The Journal of Dermatology.2023; 50(9): 1108. CrossRef
Real‐world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors
Srilatha Dasari, William Tse, Jiasheng Wang
British Journal of Haematology.2023; 202(6): 1205. CrossRef
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors
André Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, Stellio Giacomini, Sébastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Veronica Aedo-Lopez, Nuria Mederos, Sofiya Latifyan, Alfredo Addedo, Olivier Michielin, Manuela Eicher
Supportive Care in Cancer.2023;[Epub] CrossRef
CD4 T cells and toxicity from immune checkpoint blockade
Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y. Chen, Mario Sznol, Ruth Halaban, Aadel A. Chaudhuri, Aaron M. Newman
Immunological Reviews.2023; 318(1): 96. CrossRef
Anti‑PD1 therapy‑associated distal renal tubular acidosis: A case report
Xuejia Qiu, Bingnan Ren, Lingzhi Fang, Zhanjun Dong
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef
Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review
Minoru Kato, Junji Uchida
International Journal of Urology.2023; 30(12): 1068. CrossRef
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab
Manuel A. Baarslag, Joosje H. Heimovaara, Jessica S.W. Borgers, Koen J. van Aerde, Hans J.P.M. Koenen, Ruben L. Smeets, Pauline L.M. Buitelaar, Dick Pluim, Shoko Vos, Stefanie S.V. Henriet, Jan Willem B. de Groot, Martine van Grotel, Hilde Rosing, Jos H.
New England Journal of Medicine.2023; 389(19): 1790. CrossRef
Incidence and Timing of Immune-Related Adverse Events in Immune-Checkpoint Inhibitor-Treated Patients: A Retrospective Observational Study
Kou Masaki, Motoyasu Miyazaki, Hideki Kakimoto, Yuma Fukiage, Haruka Fukue, Akio Nakashima, Osamu Imakyure
Journal of Clinical Medicine.2023; 12(24): 7564. CrossRef
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
Priyatharcini Kejamurthy, K. T. Ramya Devi
Medical Oncology.2023;[Epub] CrossRef
Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From theAJRSpecial Series on Imaging of Inflammation
Sara Sheikhbahaei, Charles V. Marcus, Mohammad S. Sadaghiani, Steven P. Rowe, Martin G. Pomper, Lilja B. Solnes
American Journal of Roentgenology.2022; 218(6): 940. CrossRef
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation
Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg, Mark J. Ratain
The Journal of Clinical Pharmacology.2022; 62(4): 532. CrossRef
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, Antonietta Bacchiocchi, Noah Earland, Matthew D. Vesely, Abul Usmani, Brandon E. Turner, Chloé B. Steen, Bogdan A. Luca, Ti Badri, Gunsagar S. Gulati, Milad R. Vahid, Farnaz Khameneh, Peter K. Harri
Nature Medicine.2022; 28(2): 353. CrossRef
Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity
Ka Man Cheung, Therese Yue Man Tsui, James Chung Hang Chow
Cancer.2022; 128(13): 2549. CrossRef
CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika
Journal of Personalized Medicine.2022; 12(6): 888. CrossRef
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Research and Treatment.2022; 54(4): 1005. CrossRef
Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
Ana Cardeña-Gutiérrez, Mónica López Barahona
Frontiers in Medicine.2022;[Epub] CrossRef
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy
Afaf Abed, Ngie Law, Leslie Calapre, Johnny Lo, Vikas Bhat, Samantha Bowyer, Michael Millward, Elin S. Gray
European Journal of Cancer.2022; 172: 98. CrossRef
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma
Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling
Cancers.2022; 14(13): 3282. CrossRef
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
Ben-Max de Ruiter, Jons W. van Hattum, Djoeri Lipman, Theo M. de Reijke, R. Jeroen A. van Moorselaar, Erik J. van Gennep, A.H. Maartje Piet, Mila Donker, Tom van der Hulle, Jens Voortman, Jorg R. Oddens, Maarten C.C.M. Hulshof, Adriaan D. Bins
European Urology.2022; 82(5): 518. CrossRef
Adverse Renal Effects of Anticancer Immunotherapy: A Review
Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak, Jerzy Chudek
Cancers.2022; 14(17): 4086. CrossRef
Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
Nari Kim, Eun Sung Lee, Sang Eun Won, Mihyun Yang, Amy Junghyun Lee, Youngbin Shin, Yousun Ko, Junhee Pyo, Hyo Jung Park, Kyung Won Kim
Korean Journal of Radiology.2022; 23(11): 1089. CrossRef
Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data
Jiasheng Wang, Srilatha Dasari, Dina Elantably, Akram Alkrekshi, Yeseong David Kim
Acta Oncologica.2022; 61(9): 1157. CrossRef
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
JAMA Oncology.2022; 8(12): 1825. CrossRef
Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
Ik Shin Chin, Aman Khan, Anna Olsson-Brown, Sophie Papa, Gary Middleton, Claire Palles
npj Genomic Medicine.2022;[Epub] CrossRef
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
Deniz Can Guven, Deniz Aral Ozbek, Taha Koray Sahin, Gozde Kavgaci, Melek Seren Aksun, Enes Erul, Hasan Cagri Yildirim, Elvin Chalabiyev, Cebrayil Cebroyilov, Tolga Yildirim, Omer Dizdar, Sercan Aksoy, Suayib Yalcin, Saadettin Kilickap, Mustafa Erman, Mus
Anti-Cancer Drugs.2022;[Epub] CrossRef
Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer
Lance L. Munn, Triantafyllos Stylianopoulos, Natalie K. Jain, C. Corey Hardin, Melin J. Khandekar, Rakesh K. Jain
Clinical Cancer Research.2021; 27(10): 2706. CrossRef
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose
Gynecologic Oncology Reports.2021; 37: 100840. CrossRef
Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy
Jie Zhang, Zhujiang Dai, Cheng Yan, Daorong Wang, Dong Tang
Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3639. CrossRef
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
Jay M. Lee, Anthony W. Kim, Tomasz Marjanski, Pierre-Emmanuel Falcoz, Masahiro Tsuboi, Yi-Long Wu, Shawn W. Sun, Barbara J. Gitlitz
JTO Clinical and Research Reports.2021; 2(10): 100221. CrossRef
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael
Journal of Clinical Oncology.2021; 39(36): 4073. CrossRef
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu
Frontiers in Medicine.2021;[Epub] CrossRef

15,801 View
724 Download
102 Web of Science
110 Crossref

Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study: Xue-Song Sun, Di-Han Liu, Sai-Lan Liu, Qiu-Yan Chen, Shan-Shan Guo, Yue-Feng Wen, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Xiao-Yun Li, Jin-Jie Yan, Ming-Huang Hong, Jun Ma, Lin-Quan Tang, Hai-Qiang Mai; Cancer Res Treat. 2019;51(4):1449-1463. Published online March 7, 2019; DOI: https://doi.org/10.4143/crt.2018.688

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the survival trends and patterns of failure in patients with stage II nasopharyngeal carcinoma (NPC) treated with radiotherapy (RT) and chemotherapy over the last 20 years.
Materials and Methods
Thirty-eight hundred and eight patients diagnosed with stage II NPC between January 1990 and December 2012 were involved in this retrospective cohort study. All patients were treated with RT. According to the main imaging techniques and RT technology, we categorized these patients into four calendar periods: 1990-1996, 1997-2002, 2003-2007, and 2008-2012. Overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRFS), and distant metastasis–free survival (DMFS) were served as the clinical outcome.
Results
After a median follow-up period of 84.7 months, we observed increasing trends in survival and disease control. The 3- and 5-year OS rates increased from 87.1% and 78.7% in the first calendar period to 97.4% and 94.5% in the last calendar period, respectively (p<0.001). Additionally, significant increasing trends could be seen in the PFS and LRFS during the four calendar periods. In the subgroup analysis, the LRFS in patients older than 50 years at diagnosis showed greater improvement than younger patients. However, the rate of distant metastasis was stable and relatively low, as the 5-year DMFS ranged from 90.5% to 94.7% among the four calendar periods.
Conclusion
The survival rates in patients with stage II NPC showed increasing trends from 1990 to 2012. The advance of RT provided excellent locoregional control and enhanced OS.

Citations

Citations to this article as recorded by

Predicting disease progression from the rate of bodyweight change in nasopharyngeal carcinoma patient during radiotherapy
Jiachen Sun, Sai kit Edmond Lam, Xinzhi Teng, Jiang Zhang, Francis Kar-ho Lee, Celia Wai-yi Yip, James Chung-hang Chow, Victor Ho-fun Lee, Ying Sun, Jing Cai
Scientific Reports.2025;[Epub] CrossRef
ADAM22 acts as a novel predictive biomarker for unfavorable prognosis and facilitates metastasis via PI3K/AKT signaling pathway in nasopharyngeal carcinoma
Kaixiong Xu, Ping Jiang, Zui Chen, Xiaoqiong Gu, Ting Zhang
Pathology - Research and Practice.2024; 256: 155264. CrossRef
T1-2N1M0 nasopharyngeal carcinoma chemotherapy or not: A retrospective study
Pei-Jing Li, Ming Chen, Ye Tian, Seok Ho Lee
PLOS ONE.2023; 18(3): e0279252. CrossRef
Survival among subgroups of patients with stage II nasopharyngeal carcinoma
Shi-Ting Huang, Dan-Ke Su
Scientific Reports.2022;[Epub] CrossRef
Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study
Susanna Hilda Hutajulu, Daniel Howdon, Kartika Widayati Taroeno-Hariadi, Mardiah Suci Hardianti, Ibnu Purwanto, Sagung Rai Indrasari, Camelia Herdini, Bambang Hariwiyanto, Ahmad Ghozali, Henry Kusumo, Wigati Dhamiyati, Sri Retna Dwidanarti, I. Bing Tan, J
PLOS ONE.2021; 16(2): e0246638. CrossRef
Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
Pei-Jing Li, Yu-Lin Lai, Fang He, Yuan-Yuan Chen, Zhuo-Sheng Gu, Wei Luo, Qun Zhang
Frontiers in Pharmacology.2021;[Epub] CrossRef
Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases
Tianying Huang, Ning Su, Xuanye Zhang, Shuyun Ma, Guangzheng Zhong, Xiaopeng Tian, Qiuyan Chen, Linglong Tang, Lixia Lu, Yu Fang, Jun Cai, Qingqing Cai
Head & Neck.2020; 42(8): 1970. CrossRef
CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma

Zhi-Hui Wang, Xiao-Feng Pei, Zhi-Quan Zhu, Zhong Lin, Yin-Yan Mao, Xiao-Lu Xu, You-Li Luo, Li Zhang, Pei-Jian Peng
OncoTargets and Therapy.2020; Volume 13: 3325. CrossRef
Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA
Min Kang, Bo Tang, Jixi Li, Ziyan Zhou, Kang Liu, Rensheng Wang, Ziyan Jiang, Fangfang Bi, David Patrick, Dongin Kim, Anirban K. Mitra, Yang Yang-Hartwich
Molecular Cancer.2020;[Epub] CrossRef

7,580 View
155 Download
10 Web of Science
9 Crossref

Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway: Jun Ma, Xiao Song, Xiaowu Xu, Yiping Mou; Cancer Res Treat. 2019;51(1):194-210. Published online April 20, 2018; DOI: https://doi.org/10.4143/crt.2018.031

Abstract PDF Supplementary Material PubReader ePub

Purpose
Our aim was to detect the potential role of interleukin 11 (IL-11) in the development of chemo-resistance in gastric cancer and to reveal the mechanism involved in the process.
Materials and Methods
Here, we used flow cytometry to examine the percentage of cancer-associated-fibroblasts in tumor samples from chemo-resistant and -sensitive gastric cancer patients. Using MTT assay, we detected the cell viability under different conditions. Using quantitative real-time polymerase chain reaction and Western blotting, we determined the target expressions in mRNA and protein levels. We also performed immunohistochemistry and immunofluorescence to detect the target proteins under different conditions. Animal models were constructed to verify the potential role of IL-11 in chemo-resistant develop in vivo.
Results
Herein, we observed enriched cancer associated fibroblasts in drug resistant tumor tissues from gastric patients. Those fibroblasts facilitate the chemotherapeutic drugs resistance development through the secretion of IL-11, which activates the IL-11/IL-11R/gp130/ JAK/STAT3 anti-apoptosis signaling pathway in gastric cancer cells. We found that the combination of chemotherapeutic drugs and JAK inhibitor overcomes the resistance and increases the survival of mice with gastric cancer xenografts.
Conclusion
Ourresults demonstrated that IL-11 contributed to the obtain ofresistance to chemotherapy drugs through gp130/JAK/STAT3/Bcl2 pathway, and targeting the IL-11 signaling pathway induced by fibroblasts might be a promising strategy to overcome the multi-drugs resistant cancer in clinic.

Citations

Citations to this article as recorded by

Role of Soluble Cytokine Receptors in Gastric Cancer Development and Chemoresistance
Francesca Lospinoso Severini, Geppino Falco, Tiziana Notarangelo
International Journal of Molecular Sciences.2025; 26(6): 2534. CrossRef
The role of the tumor microenvironment and inflammatory pathways in driving drug resistance in gastric cancer: A systematic review and meta-analysis
Francesco Albano, Francesca Lospinoso Severini, Giovanni Calice, Pietro Zoppoli, Geppino Falco, Tiziana Notarangelo
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(6): 167821. CrossRef
Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure
John Gehris, Charlie Ervin, Charlotte Hawkins, Sydney Womack, Amelia M. Churillo, Jonathan Doyle, Albert J. Sinusas, Francis G. Spinale
Biochemical Pharmacology.2024; 219: 115914. CrossRef
Interleukin-6 Family of Cytokines in Cancers
Iwona Zaporowska-Stachowiak, Michał Springer, Katarzyna Stachowiak, Mary Oduah, Maciej Sopata, Katarzyna Wieczorowska-Tobis, Wiesław Bryl
Journal of Interferon & Cytokine Research.2024; 44(2): 45. CrossRef
Exosome as a crucial communicator between tumor microenvironment and gastric cancer (Review)
Menghui Wang, Hongxin Shu, Xifu Cheng, Hong Xiao, Zhenhua Jin, Nan Yao, Shengxun Mao, Zhen Zong
International Journal of Oncology.2024;[Epub] CrossRef
Tumor cell stemness in gastrointestinal cancer: regulation and targeted therapy
Kangqi Yang, Tuo Yi
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
Cancer-associated fibroblasts: protagonists of the tumor microenvironment in gastric cancer
Ece Ozmen, Tevriz Dilan Demir, Gulnihal Ozcan
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer
Peiyuan Li, Huan Zhang, Tao Chen, Yajing Zhou, Jiaoyang Yang, Jin Zhou
Matrix Biology.2024; 132: 59. CrossRef
Anlotinib inhibits cervical cancer cell proliferation and invasion by suppressing cytokine secretion in activated cancer-associated fibroblasts
Yaozu Xiong, Xiaoting Xu, Xilei Zhou, Yusuo Tong, Changhua Yu
Frontiers in Oncology.2024;[Epub] CrossRef
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution
Fusheng Zhang, Yongsu Ma, Dongqi Li, Jianlei Wei, Kai Chen, Enkui Zhang, Guangnian Liu, Xiangyu Chu, Xinxin Liu, Weikang Liu, Xiaodong Tian, Yinmo Yang
Journal of Hematology & Oncology.2024;[Epub] CrossRef
Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer
Muyang Chen, Tongshan Wang, Dianzhe Tian, Chaorui Hai, Zixuan Qiu
Heliyon.2024; 10(18): e37263. CrossRef
Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)
Yan Liu, Jun Liang, Yanping Zhang, Qie Guo
International Journal of Oncology.2024;[Epub] CrossRef
Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
Shadiya Fawzul Ameer, Muna Yusuf Mohamed, Qubaa Ahmed Elzubair, Elham Abdullatif M. Sharif, Wisam Nabeel Ibrahim
Frontiers in Oncology.2024;[Epub] CrossRef
Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer
Zhiyang Zhou, Sixuan Guo, Shuhui Lai, Tao Wang, Yao Du, Junping Deng, Shun Zhang, Ge Gao, Jiangnan Zhang
BMC Cancer.2023;[Epub] CrossRef
Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting
Xiaofeng Dai, Kaiyuan Zhu
Cancer Medicine.2023; 12(6): 7189. CrossRef
Podoplanin promotes the carcinogenicity of gastric cancer by activating ezrin and mediating the crosstalk between tumour cells and cancer‐associated fibroblasts
Yueli Tian, Xin Chen, Xiaodong Wang, Ying Song
Experimental Physiology.2023; 108(5): 740. CrossRef
Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma
Sun Miaomiao, Wang Xiaoqian, Shou Yuwei, Chen Chao, Yang Chenbo, Liang Yinghao, Hong Yichen, Shu Jiao, Chen Kuisheng
Scientific Reports.2023;[Epub] CrossRef
An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma
Brianna J. McIntosh, Griffin G. Hartmann, Sean A. Yamada‐Hunter, Phillip Liu, Camille F. Williams, Julien Sage, Jennifer R. Cochran
Bioengineering & Translational Medicine.2023;[Epub] CrossRef
Targeting carcinoma‐associated mesothelial cells with antibody–drug conjugates in ovarian carcinomatosis
Lucía Pascual‐Antón, Pilar Sandoval, Guadalupe T González‐Mateo, Valeria Kopytina, Henar Tomero‐Sanz, Eva María Arriero‐País, José Antonio Jiménez‐Heffernan, Myriam Fabre, Isabel Egaña, Cristina Ferrer, Laureano Simón, Lucía González‐Cortijo, Ricardo Sain
The Journal of Pathology.2023; 261(2): 238. CrossRef
Chemoresistant fibroblasts dictate neoadjuvant chemotherapeutic response of head and neck cancer via TGFα-EGFR paracrine signaling
Liangping Su, Sangqing Wu, Cheng Huang, Xianhua Zhuo, Jiali Chen, Xue Jiang, Xiangzhan Kong, Cui Lv, Qiuping Xu, Ping Han, Xiaoming Huang, Ping-Pui Wong
npj Precision Oncology.2023;[Epub] CrossRef
A bibliometric and visual analysis of cancer-associated fibroblasts
Wei-Chen Yuan, Jie-Xiang Zhang, Hai-Bin Chen, Ying Yuan, Yu-Pei Zhuang, Hong-Li Zhou, Mu-Han Li, Wen-Li Qiu, Hong-Guang Zhou
Frontiers in Immunology.2023;[Epub] CrossRef
The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword
Mohammad Heydarian, Mohammadjavad Mohammadtaghizadeh, Mahboobeh Shojaei, Marziyeh Babazadeh, Sadegh Abbasian, Mehran Amrovani
Molecular Biology Reports.2022; 49(1): 605. CrossRef
Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
Pradip De, Jennifer Aske, Raed Sulaiman, Nandini Dey
Cancers.2022; 14(6): 1519. CrossRef
Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone
Ruo-Yi Huang, Hao-Wei Kou, Puo-Hsien Le, Chia-Jung Kuo, Tsung-Hsing Chen, Shang-Yu Wang, Jen-Shi Chen, Ta-Sen Yeh, Jun-Te Hsu
Journal of Personalized Medicine.2022; 12(4): 555. CrossRef
Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures
Bing Feng, Jianzhong Wu, Bo Shen, Feng Jiang, Jifeng Feng
Cancer Cell International.2022;[Epub] CrossRef
Curcumin inhibits the cancer‑associated fibroblast‑derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway
In-Hye Ham, Lei Wang, Dagyeong Lee, Jongsu Woo, Tae Kim, Hye Jeong, Hye Oh, Kyeong Choi, Tae-Min Kim, Hoon Hur
International Journal of Oncology.2022;[Epub] CrossRef
Role of Interleukins and New Perspectives in Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Marlena Janiczek-Polewska, Łukasz Szylberg, Julian Malicki, Andrzej Marszałek
Biomedicines.2022; 10(7): 1600. CrossRef
Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer
Jason Hongting Leung, Benjamin Ng, Wei-Wen Lim
Cells.2022; 11(14): 2257. CrossRef
Over-expression of NFYB affects stromal cells reprogramming and predicts worse survival in gastric cancer patients
Tailiang Lu, Chenglong Li, Cailing Xiang, Yongqiang Gong, Wei Peng, Futao Hou, Chaowu Chen
Aging.2022; 14(19): 7851. CrossRef
Drug Resistance in Cancers: A Free Pass for Bullying
Jing Li, Xiao Li, Qie Guo
Cells.2022; 11(21): 3383. CrossRef
Exosomal long non-coding RNAs: novel molecules in gastrointestinal cancers’ progression and diagnosis
Mohammad Roshani, Ghazaleh Baniebrahimi, Mahboubeh Mousavi, Noushid Zare, Reza Sadeghi, Reza Salarinia, Amirhossein Sheida, Danial Molavizadeh, Sara Sadeghi, Farzaneh Moammer, Mohammad Reza Zolfaghari, Hamed Mirzaei
Frontiers in Oncology.2022;[Epub] CrossRef
CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging
Tao Zhang, Ping Zhang, Hong-Xia Li
International Journal of Nanomedicine.2021; Volume 16: 561. CrossRef
PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma
Zhi Yu, Dan Wang, Yingying Tang
Molecular and Cellular Biochemistry.2021; 476(5): 2001. CrossRef
Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis
Peng Deng, Ming Sun, Wen-Yan Zhao, Bin Hou, Kai Li, Tao Zhang, Feng Gu
World Journal of Gastroenterology.2021; 27(6): 487. CrossRef
Cancer-Associated Fibroblast-Induced Resistance to Chemotherapy and Radiotherapy in Gastrointestinal Cancers
In-Hye Ham, Dagyeong Lee, Hoon Hur
Cancers.2021; 13(5): 1172. CrossRef
Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy
Takahiro Ishii, Ayako Suzuki, Takeshi Kuwata, Shoshi Hisamitsu, Hiroko Hashimoto, Yuuki Ohara, Kazuyoshi Yanagihara, Shuichi Mitsunaga, Takayuki Yoshino, Takahiro Kinoshita, Atsushi Ochiai, Kohei Shitara, Genichiro Ishii
Gastric Cancer.2021; 24(4): 810. CrossRef
Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential
Adriana Carino, Luigina Graziosi, Silvia Marchianò, Michele Biagioli, Elisabetta Marino, Valentina Sepe, Angela Zampella, Eleonora Distrutti, Annibale Donini, Stefano Fiorucci
Frontiers in Oncology.2021;[Epub] CrossRef
Inflammation-Induced Tumorigenesis and Metastasis
Sana Hibino, Tetsuro Kawazoe, Hidenori Kasahara, Shinji Itoh, Takatsugu Ishimoto, Mamiko Sakata-Yanagimoto, Koji Taniguchi
International Journal of Molecular Sciences.2021; 22(11): 5421. CrossRef
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Yanghong Ni, Xiaoting Zhou, Jia Yang, Houhui Shi, Hongyi Li, Xia Zhao, Xuelei Ma
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Fanglong Wu, Jin Yang, Junjiang Liu, Ye Wang, Jingtian Mu, Qingxiang Zeng, Shuzhi Deng, Hongmei Zhou
Signal Transduction and Targeted Therapy.2021;[Epub] CrossRef
Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy
Pradip De, Jennifer Aske, Nandini Dey
Cancers.2021; 13(20): 5246. CrossRef
Induction of interleukin-11 mediated by RhoA GTPase during human cytomegalovirus lytic infection
Saud Alarifi, Saad Alkahtani, Ahmed A. Al-Qahtani, Christos Stournaras, George Sourvinos
Cellular Signalling.2020; 70: 109599. CrossRef
Tumor-Secreted Exosomal lncRNA POU3F3 Promotes Cisplatin Resistance in ESCC by Inducing Fibroblast Differentiation into CAFs
Yusuo Tong, Lili Yang, Changhua Yu, Weiguo Zhu, Xilei Zhou, Yaozu Xiong, Wanwei Wang, Fuzhi Ji, Dongcheng He, Xiufeng Cao
Molecular Therapy - Oncolytics.2020; 18: 1. CrossRef
STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
Milad Ashrafizadeh, Ali Zarrabi, Sima Orouei, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Mohammadi, Kiavash Hushmandi, Yashar Gharehaghajlou, Pooyan Makvandi, Masoud Najafi, Reza Mohammadinejad
Biology.2020; 9(6): 126. CrossRef
Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma
Jose J. G. Marin, Laura Perez-Silva, Rocio I. R. Macias, Maitane Asensio, Ana Peleteiro-Vigil, Anabel Sanchez-Martin, Candela Cives-Losada, Paula Sanchon-Sanchez, Beatriz Sanchez De Blas, Elisa Herraez, Oscar Briz, Elisa Lozano
Cancers.2020; 12(8): 2116. CrossRef
Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells
Changying Shi, Jiamei Yang, Longmiao Hu, Boyi Liao, Liang Qiao, Weifeng Shen, Feng Xie, Guoqing Zhu
Aging.2020; 12(15): 15546. CrossRef
Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung adenocarcinoma
Jia-Ru Wei, Jun Dong, Lei Li
Aging.2020; 12(13): 13220. CrossRef
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
Gemma van Duijneveldt, Michael D.W. Griffin, Tracy L. Putoczki
Clinical Science.2020; 134(16): 2091. CrossRef
Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
In-Hye Ham, Dagyeong Lee, Hoon Hur
Journal of Oncology.2019; 2019: 1. CrossRef
The long non‐coding RNA OLC8 enhances gastric cancer by interaction with IL‐11
Rongjia Zhou, Zhanbin Wu, Xixiang Deng, Haojun Chen
Journal of Clinical Laboratory Analysis.2019;[Epub] CrossRef
Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells
Sabino Russi, Henu Kumar Verma, Simona Laurino, Pellegrino Mazzone, Giovanni Storto, Anna Nardelli, Pietro Zoppoli, Giovanni Calice, Francesco La Rocca, Alessandro Sgambato, Valeria Lucci, Geppino Falco, Vitalba Ruggieri
International Journal of Molecular Sciences.2019; 20(15): 3736. CrossRef
The pro-tumorigenic host response to cancer therapies
Yuval Shaked
Nature Reviews Cancer.2019; 19(12): 667. CrossRef
Dracorhodin perchlorate induces apoptosis and G2/M cell cycle arrest in human esophageal squamous cell carcinoma through inhibition of the JAK2/STAT3 and AKT/FOXO3a pathways
Zhengyang Lu, Chenyang Lu, Cheng Li, Yan Jiao, Yanqing Li, Guangxin Zhang
Molecular Medicine Reports.2019;[Epub] CrossRef
Near-infrared fluorescent labeled CGRRAGGSC peptides for optical imaging of IL-11Rα in athymic mice bearing tumor xenografts
Tiannv Li, Jin Sun, Yao Hu, Min Yang, Haibin Shi, Lijun Tang
The Journal of Biomedical Research.2019; 33(6): 391. CrossRef

14,984 View
472 Download
62 Web of Science
54 Crossref

Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis: Yang Li, Lin-Quan Tang, Li-Ting Liu, Shan-Shan Guo, Yu-Jing Liang, Xue-Song Sun, Qing-Nan Tang, Jin-Xin Bei, Jing Tan, Shuai Chen, Jun Ma, Chong Zhao, Qiu-Yan Chen, Hai-Qiang Mai; Cancer Res Treat. 2018;50(4):1304-1315. Published online January 8, 2018; DOI: https://doi.org/10.4143/crt.2017.463

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate the long-term clinical outcome and toxicity of induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) compared with CCRT alone for the treatment of children and adolescent locoregionally advanced nasopharyngeal carcinoma (LACANPC).
Materials and Methods
A total of 194 locoregionally advanced nasopharyngeal carcinoma patients youngerthan 21 years who received CCRT with or without IC before were included in the study population. Overall survival (OS) rate, progression-free survival (PFS) rate, locoregional recurrence-free survival (LRFS) rate, and distant metastasis-free survival (DMFS) rate were assessed by the Kaplan-Meier method and a log-rank test. Treatment toxicities were clarified and compared between two groups.
Results
One hundred and thiry of 194 patients received IC+CCRT. Patients who were younger and with more advanced TNM stage were more likely to receive IC+CCRT and intensive modulated radiotherapy. The addition of IC before CCRT failed to improve survival significantly. The matched analysis identified 43 well-balanced patients in both two groups. With a median follow-up of 51.5 months, no differences were found between the IC+CCRT group and the CCRT group in 5-year OS (83.7% vs. 74.6%, p=0.153), PFS (79.2% vs. 73.4%, p=0.355), LRFS (97.7% vs. 88.2%, p=0.083), and DMFS (81.6% vs. 81.6%, p=0.860). N3 was an independent prognostic factor predicting poorer OS, PFS, and DMFS. The addition of IC was associated with increased rates of grade 3 to 4 neutropenia.
Conclusion
This study failed to demonstrate that adding IC before CCRT could provide a significant additional survival benefit for LACANPC patients. Further investigations are warranted.

Citations

Citations to this article as recorded by

Nasopharyngeal Carcinoma in Children, Current Treatment Approach
Tal Ben-Ami
Journal of Pediatric Hematology/Oncology.2024; 46(3): 117. CrossRef
Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study
Ya-Nan Jin, Zhao-Hui Ruan, Wan-Wei Cao, Lin Yang, Wei Yao, Xiao-Feng Pei, Wang-Jian Zhang, Tia Marks, Ji-Jin Yao, Liang-Ping Xia
Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11929. CrossRef
Epidemiology and treatment of head and neck malignancies in the AYA generation
Takahiro Asakage
International Journal of Clinical Oncology.2022; 27(3): 465. CrossRef
Association of Treatment Advances With Survival Rates in Pediatric Patients With Nasopharyngeal Carcinoma in China, 1989-2020
Yu-Jing Liang, Li-Ting Liu, Yang Li, Pan Wang, Mei-Juan Luo, Dong-Xiang Wen, Qiu-Yan Chen, Hai-Qiang Mai
JAMA Network Open.2022; 5(3): e220173. CrossRef
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis
Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
British Journal of Cancer.2022; 127(7): 1239. CrossRef
Exploring the Optimal Chemotherapy Strategy for Locoregionally Advanced Children and Adolescent Nasopharyngeal Carcinoma Based on Pretreatment Epstein-Barr Virus DNA Level in the Era of Intensity Modulated Radiotherapy
Ziyi Zeng, Chen Chen, Lanlan Guo, Cheng Zhang, Lei Chen, Chuanping Yuan, Lixia Lu
Frontiers in Oncology.2021;[Epub] CrossRef
Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study
Ya-Nan Jin, Ji-Jin Yao, Ya-Fei You, Hui-Jiao Cao, Zi-Zi Li, Dan-Ling Dai, Wang-Jian Zhang, Tia Marks, Bei Zhang, Liang-Ping Xia
Radiotherapy and Oncology.2021; 161: 83. CrossRef
Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period
Rejin Kebudi, Sema Bay Buyukkapu, Omer Gorgun, Kübra Ozkaya, Rasim Meral, Inci Ayan, Musa Altun
Pediatric Blood & Cancer.2021;[Epub] CrossRef
Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA
Yu-Jing Liang, Dong-Xiang Wen, Mei-Juan Luo, Lin-Quan Tang, Shan-Shan Guo, Pan Wang, Qiu-Yan Chen, Li-Ting Liu, Hai-Qiang Mai
European Journal of Cancer.2021; 159: 133. CrossRef
Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
IEEE Access.2021; 9: 98701. CrossRef
LHX2 Facilitates the Progression of Nasopharyngeal Carcinoma via Activation of the FGF1/FGFR Axis
Tao Xie, Kunpeng Du, Wei Liu, Chunshan Liu, Baiyao Wang, Yunhong Tian, Rong Li, Xiaoting Huang, Jie Lin, Haifeng Jian, Jian Zhang, Yawei Yuan
SSRN Electronic Journal .2021;[Epub] CrossRef
Prognostic impact of immunohistopathologic features in definitive radiation therapy for nasopharyngeal cancer patients
Naoya Murakami, Taisuke Mori, Yuko Kubo, Seiichi Yoshimoto, Kimiteru Ito, Yoshitaka Honma, Takao Ueno, Kenya Kobayashi, Hiroyuki Okamoto, Narikazu Boku, Kana Takahashi, Koji Inaba, Kae Okuma, Hiroshi Igaki, Yuko Nakayama, Jun Itami
Journal of Radiation Research.2020; 61(1): 161. CrossRef
The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
Bi-Cheng Wang, Bo-Ya Xiao, Guo-He Lin, Chang Wang, Quentin Liu
BMC Cancer.2020;[Epub] CrossRef
Update in pediatric nasopharyngeal undifferentiated carcinoma
Line Claude, Emmanuel Jouglar, Loig Duverge, Daniel Orbach
The British Journal of Radiology.2019;[Epub] CrossRef

8,862 View
211 Download
19 Web of Science
14 Crossref

Proposal of a Pretreatment Nomogram for Predicting Local Recurrence after Intensity-Modulated Radiation Therapy in T4 Nasopharyngeal Carcinoma: A Retrospective Review of 415 Chinese Patients: Lu-Lu Zhang, Yi-Yang Li, Jiang Hu, Guan-Qun Zhou, Lei Chen, Wen-Fei Li, Ai-Hua Lin, Jun Ma, Zhen-Yu Qi, Ying Sun; Cancer Res Treat. 2018;50(4):1084-1095. Published online November 15, 2017; DOI: https://doi.org/10.4143/crt.2017.359

Abstract PDF PubReader ePub

Purpose
Local relapse-free survival (LRFS) differs widely among patients with T4 category nasopharyngeal carcinoma (NPC). We aimed to build a nomogram incorporating clinicopathological information to predict LRFS in T4 NPC after definitive intensity-modulated radiation therapy (IMRT).
Materials and Methods
Retrospective study of 415 Chinese patients with non-metastatic T4 NPC treated with definitive IMRT with or without chemotherapy at our cancer center between October 2009 and September 2013. The nomogram for LRFS at 3 and 5 years was generated based on multivariate Cox proportional hazards regression, and validated using bootstrap resampling, assessing discriminative performance using the concordance index (C-index) and determining calibration ability via calibration curves.
Results
Five-year LRFS was 88.8%. We identified and incorporated four independent prognostic factors for LRFS: ethmoid sinus invasion, primary gross tumor volume, age, and pretreatment body mass index. The C-index of the nomogram for local recurrence was 0.732 (95% confidence interval, 0.726 to 0.738), indicating excellent predictive accuracy. The calibration curve revealed excellent agreement between nomogram-predicted and observed LRFS probabilities. Risk subgroups based on total point score cutoff values enabled effective discrimination of LRFS.
Conclusion
This pretreatment nomogram enables clinicians to accurately predict LRFS in T4 NPC after definitive IMRT, and could help to facilitate personalized patient counselling and treatment strategies.

Citations

Citations to this article as recorded by

Radiomics and Deep Learning in Nasopharyngeal Carcinoma: A Review
Zipei Wang, Mengjie Fang, Jie Zhang, Linquan Tang, Lianzhen Zhong, Hailin Li, Runnan Cao, Xun Zhao, Shengyuan Liu, Ruofan Zhang, Xuebin Xie, Haiqiang Mai, Sufang Qiu, Jie Tian, Di Dong
IEEE Reviews in Biomedical Engineering.2024; 17: 118. CrossRef
Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma
Huan Liang, Weilin Tan, Jie Wang, Mengdan Li, Hua Pang, Xiaohui Wang, Lu Yang, Xingguo Jing
Annals of Nuclear Medicine.2024; 38(10): 802. CrossRef
Can Epstein–Barr virus‐deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Qun Zhang, Zhen‐Wei Peng, Zhuo‐Sheng Gu, Yan Wang, Fang He, Wen‐Bin Zhao, Wei Luo, Yong‐Yu Mei
Cancer Medicine.2023; 12(1): 223. CrossRef
Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity‐modulated radiotherapy treatment of T4 nasopharyngeal carcinoma
Yanyan Chen, Quxia Zhang, Tianzhu Lu, Cairong Hu, Jingfeng Zong, Yun Xu, Wei Zheng, Lisha Chen, Senan Lin, Sufang Qiu, Luying Xu, Jianji Pan, Qiaojuan Guo, Shaojun Lin
Head & Neck.2023; 45(5): 1130. CrossRef
Multi-task deep learning-based radiomic nomogram for prognostic prediction in locoregionally advanced nasopharyngeal carcinoma
Bingxin Gu, Mingyuan Meng, Mingzhen Xu, David Dagan Feng, Lei Bi, Jinman Kim, Shaoli Song
European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(13): 3996. CrossRef
Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma
Shan-Shan Guo, Yan-Zhou Chen, Li-Ting Liu, Rong-Ping Liu, Yu-Jing Liang, Dong-Xiang Wen, Jing Jin, Lin-Quan Tang, Hai-Qiang Mai, Qiu-Yan Chen
BMC Cancer.2022;[Epub] CrossRef
DeepMTS: Deep Multi-Task Learning for Survival Prediction in Patients With Advanced Nasopharyngeal Carcinoma Using Pretreatment PET/CT
Mingyuan Meng, Bingxin Gu, Lei Bi, Shaoli Song, David Dagan Feng, Jinman Kim
IEEE Journal of Biomedical and Health Informatics.2022; 26(9): 4497. CrossRef
Development and Validation of Prognostic Nomograms Based on Gross Tumor Volume and Cervical Nodal Volume for Nasopharyngeal Carcinoma Patients With Concurrent Chemoradiotherapy
Cui-Dai Zhang, Mei Li, Ying-Ji Hong, Ze-Man Cai, Kai-Chun Huang, Zhi-Xiong Lin, Zhi-Ning Yang
Frontiers in Oncology.2021;[Epub] CrossRef
Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area
Ji-Jin Yao, Li Lin, Tian-Sheng Gao, Wang-Jian Zhang, Wayne R. Lawrence, Jun Ma, Ying Sun
Cancer Research and Treatment.2021; 53(3): 657. CrossRef
Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery
Yang-Yu Huang, Lei-Lei Wu, Xuan Liu, Shen-Hua Liang, Guo-Wei Ma
BMC Cancer.2021;[Epub] CrossRef
Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
Bingxin Gu, Jianping Zhang, Guang Ma, Shaoli Song, Liqun Shi, Yingjian Zhang, Zhongyi Yang
BMC Cancer.2020;[Epub] CrossRef
Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics

Peiyun Long, Youya Zang, Huan Wang, Xiumei Liang, Xuekun Xie, Zhiwei Han, Dongyi Lin, Zongyu Wang, Shan Huang, Chuang Chen
OncoTargets and Therapy.2020; Volume 13: 2093. CrossRef
Impact of Paranasal Sinus Invasion on Oncologic and Dosimetric Outcomes in Nasopharyngeal Carcinoma Following Intensity-Modulated Radiation Therapy—Implications for Risk Stratification and Planning Optimization
Xin Zhou, Xiayun He, Fen Xue, Xiaomin Ou, Chaosu Hu
Frontiers in Oncology.2020;[Epub] CrossRef
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients
Nicola Alessandro Iacovelli, Alessandro Cicchetti, Anna Cavallo, Salvatore Alfieri, Laura Locati, Eliana Ivaldi, Rossana Ingargiola, Domenico A. Romanello, Paolo Bossi, Stefano Cavalieri, Chiara Tenconi, Silvia Meroni, Giuseppina Calareso, Marco Guzzo, Ce
Frontiers in Oncology.2020;[Epub] CrossRef
Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma
Lu-Lu Zhang, Fei Xu, Di Song, Meng-Yao Huang, Yong-Shi Huang, Qi-Ling Deng, Yi-Yang Li, Jian-Yong Shao
JAMA Network Open.2020; 3(12): e2029882. CrossRef
Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups
En-Hong Zhuo, Wei-Jing Zhang, Hao-Jiang Li, Guo-Yi Zhang, Bing-Zhong Jing, Jian Zhou, Chun-Yan Cui, Ming-Yuan Chen, Ying Sun, Li-Zhi Liu, Hong-Min Cai
European Radiology.2019; 29(10): 5590. CrossRef
Impact of paranasal sinus invasion on advanced nasopharyngeal carcinoma treated with intensity‐modulated radiation therapy: the validity of advanced T stage of AJCC/UICC eighth edition staging system
Ying Wang, Jie Zhao, Yajie Zhao, Zhen Yang, Mingjun Lei, Zhanzhan Li, Rui Wei, Dengming Chen, Yuxiang He, Liangfang Shen
Cancer Medicine.2018; 7(7): 2826. CrossRef

8,972 View
202 Download
18 Web of Science
17 Crossref

Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area: Cheng Xu, Shi-Ping Yang, Yuan Zhang, Ling-Long Tang, Guan-Qun Zhou, Xu Liu, Yan-Ping Mao, Rui Guo, Wen-Fei Li, Lei Chen, Ai-Hua Lin, Ying Sun, Jun Ma; Cancer Res Treat. 2018;50(3):777-790. Published online July 24, 2017; DOI: https://doi.org/10.4143/crt.2017.255

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the effect of neutropenia during the first cycle of induction chemotherapy (IC-1) on survival in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
Eligible patients (n=545) with LANPC receiving IC+concurrent chemoradiotherapy were included. Based on nadir neutrophil afterIC-1, all patientswere categorized into three groups: no/grade 1-2/grade 3-4 neutropenia. Five-year overall survival (OS) and disease-free survival (DFS) were compared between groups and subgroups stratified by IC regimen. We also explored the occurrence of IC-1–induced myelosuppression events and the minimal value of post-treatment neutrophil-to-lymphocyte ratio (post-NLR_min). Univariate/multivariate analyses were performed to investigate the effect of IC-1–induced neutropenia, timing of neutropenia, number of myelosuppression events, and high post-NLR_min on OS/DFS.
Results
Grade 1-2/grade 3-4 neutropeniawere associatedwith poorer OS/DFS than no neutropenia (all p < 0.05); OS/DFS were not significantly different between patients experiencing grade 1-2 vs. 3-4 neutropenia. Neutropenia had no significant effect on OS/DFS in patients receiving docetaxel–cisplatin–5-fluorouracil (TPF). Grade 1-2 (grade 3-4) neutropenia negatively influenced OS/DFS in patients receiving cisplatin–5-fluorouracil (PF) (PF and docetaxel–cisplatin [TP]; all p < 0.05). Neutropenia, two/three myelosuppression events, and high post-NLR_min (≥ 1.33) was most frequent on days 5-10, second and third week of IC-1, respectively. After adjustment for covariates, IC-1–induced neutropenia, two/three myelosuppression events, and post-NLR_min ≥ 1.33were validated as negative predictors of OS/DFS (all p < 0.05); timing of neutropenia had no significant effect.
Conclusion
Occurrence of neutropenia, number of myelosuppression events, and high post-NLR_min during PF/TP IC-1 have prognostic value for poor survival in LANPC.

Citations

Citations to this article as recorded by

Prospective clinical study of the efficacy and safety of different doses of PEG recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventing leukopenia/neutropenia caused by concurrent chemoradiotherapy for cervical cancer
Tingting Yu, Yiwei Zhang, Jiawen Li, Zhuo Li, Rui Tong
Holistic Integrative Oncology.2024;[Epub] CrossRef
Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma
Lu‐Lu Zhang, Xi Chen, Ying‐Ying Huang, Chi‐Xiong Liang, Meng‐Yun Qiang, Zhuo‐Chen Cai, Ze‐Jiang Zhan, Ying Deng, Jia‐Yu Zhou, Hao‐Yang Huang, Xiang Guo, Xing Lv
Cancer Medicine.2023; 12(13): 14084. CrossRef
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)
Jun Wang, Baosheng Li
Precision Radiation Oncology.2023; 7(3): 150. CrossRef
Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2020 edition)
Jun Wang, Baosheng Li
Precision Radiation Oncology.2021; 5(1): 4. CrossRef
Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma
Yuanji Xu, Zijie Wu, Wangzhong Ye, Youping Xiao, Wei Zheng, Qinyan Chen, Penggang Bai, Zhizhong Lin, Chuanben Chen
BMC Cancer.2021;[Epub] CrossRef
Time-to-Event Supervised Genetic Algorithm Enables Induction Chemotherapy Decision Making for Nasopharyngeal Carcinoma
Demin Liu, Haojiang Li, Liyang Wu, Shuchao Chen, Tianqiao Zhang, Wenjie Huang, Guangying Ruan, Sai Li, Lizhi Liu, Hongbo Chen
IEEE Access.2021; 9: 98701. CrossRef
Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma
Dan Ou, Xiaoshen Wang, Mingyao Wu, Fen Xue, Yujiao Li, Chaosu Hu, Xiayun He
Strahlentherapie und Onkologie.2020; 196(3): 252. CrossRef
Amelioration of cyclophosphamide-induced myelosuppression during treatment to rats with breast cancer through low-intensity pulsed ultrasound
Wei Wang, Dong Luo, Junlin Chen, Jinyun Chen, Yi Xia, Wenzhi Chen, Yan Wang
Bioscience Reports.2020;[Epub] CrossRef

12,328 View
241 Download
7 Web of Science
8 Crossref

A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry: Jia-Wei Lv, Xiao-Dan Huang, Yu-Pei Chen, Guan-Qun Zhou, Ling-Long Tang, Yan-Ping Mao, Wen-Fei Li, Ai-Hua Lin, Jun Ma, Ying Sun; Cancer Res Treat. 2018;50(2):324-334. Published online April 19, 2017; DOI: https://doi.org/10.4143/crt.2016.544

Abstract PDF PubReader ePub

Purpose
Conditional survival (CS) provides important information on survival for a period of time after diagnosis. Currently, information on CS patterns of patients with nasopharyngeal carcinoma (NPC) is lacking. We aimed to analyze survival rate over time and estimate CS for NPC patients using a national population-based registry.
Materials and Methods
Patients diagnosed with NPC between 1973 and 2007 with at least 5-year follow-up were identified from the Surveillance Epidemiology End Results registry. Traditional survival rates and crude CS estimateswere calculated using Kaplan-Meier analysis. Risk-adjusted survival curves were plotted from the proportional hazards model using the correct group prognosis method.
Results
For 7,713 patients analyzed, adjusted baseline 5-year overall survival improved significantly from 36.0% in patients diagnosed in 1973-1979, 41.7% in 1980-1989, 46.6% in 1990- 1999, to 54.7% in 2000-2007 (p < 0.01). CS analysis demonstrated that for every additional year survived, adjusted probability of surviving the next 5 years increased from 66.7% (localized), 54.0% (regional), and 35.3% (distant) at the time of diagnosis, to 83.7% (localized), 75.0% (regional), and 62.2% (distant) for patients who had survived 5 years. Adjusted 5-year CS differed among age, sex, tumor histology, ethnicity, and stage subgroups initially, but converged with time.
Conclusion
Treatment outcomes of NPC patients have greatly improved over the decades. Increases in CS become more prominent in patients with distant disease than in those with localized or regional disease as patients survive longer. CS provides more dynamic prognostic information for patients who have survived a period of time after diagnosis.

Citations

Citations to this article as recorded by

A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
Anna Spreafico, Eric Winquist, Cheryl Ho, Brian O’Sullivan, Nathaniel Bouganim, Neil Chua, Sarah Doucette, Lillian L. Siu, Desiree Hao
Current Oncology.2025; 32(1): 48. CrossRef
Role of combined surgical and radiotherapy treatment in nonmetastatic WHO I nasopharyngeal carcinoma patients
Zi-meng Wang, Si-yu Zhu, Qin Wang, Chong-yang Duan, Si-han Liu, Rui You, Ming-Yuan Chen, Pei-Yu Huang
Acta Oto-Laryngologica.2024; 144(4): 325. CrossRef
Health and Well-Being Needs Among Head and Neck Cancer Caregivers – A Systematic Review
Sarah Benyo, Chandat Phan, Neerav Goyal
Annals of Otology, Rhinology & Laryngology.2023; 132(4): 449. CrossRef
Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach
Tianzhu Lu, Hanchuan Xu, Wanfang Huang, Jingfeng Zong, Caizhu Pan, Chaobin Huang, Youping Xiao, Bijuan Chen, Jingao Li, Jianji Pan, Shaojun Lin, Fang Guo, Qiaojuan Guo
Radiotherapy and Oncology.2023; 185: 109716. CrossRef
Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors
Jianing Luo, Xiaonan Hu, Xiaofeng Ge
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10181. CrossRef
Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma
James C. H. Chow, Wah Cheuk, William C. S. Cho, Chi-Fai Wong, Dennis W. Y. Au, Anthony H. P. Tam, Rachel C. W. Wong, Jeffrey C. H. Chan, Simon C. C. Law, Roger K. C. Ngan, Kam-Hung Wong, Ka-Man Cheung
JAMA Network Open.2023; 6(7): e2323890. CrossRef
Analysis of conditional survival for primary hepatocellular carcinoma with narrow-margin hepatectomy: a large-sample, dual-center, retrospective study
Jie Kong, Tingfeng Huang, Jianxi Zhang, Shichuan Tang, Hongzhi Liu, Jingfeng Liu, Yongyi Zeng
HPB.2022;[Epub] CrossRef
Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments
Oren Shechter, Daniel G. Sausen, Elisa S. Gallo, Harel Dahari, Ronen Borenstein
International Journal of Molecular Sciences.2022; 23(22): 14389. CrossRef
Health literacy impacts self-management, quality of life and fear of recurrence in head and neck cancer survivors
Nicholas Clarke, Simon Dunne, Laura Coffey, Linda Sharp, Deirdre Desmond, Jean O’Conner, Eleanor O’Sullivan, Conrad Timon, Claire Cullen, Pamela Gallagher
Journal of Cancer Survivorship.2021; 15(6): 855. CrossRef
Development and validation of a web‐based calculator to predict individualized conditional risk of site‐specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases
Chen‐Fei Wu, Jia‐Wei Lv, Li Lin, Yan‐Ping Mao, Bin Deng, Wei‐Hong Zheng, Dan‐Wan Wen, Yue Chen, Jia Kou, Fo‐Ping Chen, Xing‐Li Yang, Zi‐Qi Zheng, Zhi‐Xuan Li, Si‐Si Xu, Jun Ma, Ying Sun
Cancer Communications.2021; 41(1): 37. CrossRef
Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta, Indonesia: A hospital-based retrospective study
Susanna Hilda Hutajulu, Daniel Howdon, Kartika Widayati Taroeno-Hariadi, Mardiah Suci Hardianti, Ibnu Purwanto, Sagung Rai Indrasari, Camelia Herdini, Bambang Hariwiyanto, Ahmad Ghozali, Henry Kusumo, Wigati Dhamiyati, Sri Retna Dwidanarti, I. Bing Tan, J
PLOS ONE.2021; 16(2): e0246638. CrossRef
Prognostic models for 1-year survival of NPC after radiotherapy in different ages
Qu-xia Zhang, Lv-ping Zhuang, Zhong-yang Lin
European Archives of Oto-Rhino-Laryngology.2021; 278(12): 4955. CrossRef
Characteristics of Early Death in Patients With Localized Nasopharyngeal Cancer: A Population-Based SEER Analysis
Haiyan Chen, Zhiheng Huang, Liubo Chen, Yanlin Li, Tiehong Zhao, Qichun Wei
Frontiers in Oncology.2021;[Epub] CrossRef
Stage‐dependent conditional survival and failure hazard of non‐metastatic nasopharyngeal carcinoma after intensity‐modulated radiation therapy: Clinical implications for treatment strategies and surveillance
Jingbo Wang, Xiaodong Huang, Shiran Sun, Kai Wang, Yuan Qu, Xuesong Chen, Runye Wu, Ye Zhang, Qingfeng Liu, Jianghu Zhang, Jingwei Luo, Jianping Xiao, Li Gao, Guozhen Xu, Chen Hu, Ye‐Xiong Li, Junlin Yi
Cancer Medicine.2021; 10(11): 3613. CrossRef
Effects of radiotherapy in patients with nasopharyngeal carcinoma under continuous-discrete mixed mathematical model and comparison on the fungal and pathogen infection indexes before and after nutritional supplementation
Yi Li, Xuan Li, Sahar Issa, Khairi Mohamed Omar
Results in Physics.2021; 26: 104355. CrossRef
Histological subtype remains a prognostic factor for survival in nasopharyngeal carcinoma patients
Xing‐Xi Pan, Ya‐Jie Liu, Wen Yang, Yong‐Fa Chen, Wu‐Bing Tang, Chu‐Rong Li
The Laryngoscope.2020;[Epub] CrossRef
Association of Ambient Air Pollution with Nasopharyngeal Carcinoma Incidence in Ten Large Chinese Cities, 2006–2013
Tianan Yang, Yexin Liu, Weigang Zhao, Zhenjiao Chen, Jianwei Deng
International Journal of Environmental Research and Public Health.2020; 17(6): 1824. CrossRef
Increasing incidence and improving survival of oral tongue squamous cell carcinoma
Yi-Jun Kim, Jin Ho Kim
Scientific Reports.2020;[Epub] CrossRef
Identification of differentially expressed circular RNAs in human nasopharyngeal carcinoma
Hanwei Wu, Yuchen Liu, Hongfang Duan, Xiaoqin Fan, Yujie Wang, Jian Song, Jinghong Han, Ming Yang, Lu Lu, Guohui Nie
Cancer Biomarkers.2020; 29(4): 483. CrossRef
PP‐22 promotes autophagy and apoptosis in the nasopharyngeal carcinoma cell line CNE‐2 by inducing endoplasmic reticulum stress, downregulating STAT3 signaling, and modulating the MAPK pathway
Gui‐Xiang Tan, Xin‐Ning Wang, Yun‐Yun Tang, Wan‐Jing Cen, Zhen‐Hua Li, Guo‐Cai Wang, Jian‐Wei Jiang, Xi‐Cheng Wang
Journal of Cellular Physiology.2019; 234(3): 2618. CrossRef
microRNA-342-3p targets FOXQ1 to suppress the aggressive phenotype of nasopharyngeal carcinoma cells
Zheqing Cui, Yulin Zhao
BMC Cancer.2019;[Epub] CrossRef
Changing odds of survival over time among patients undergoing surgical resection of extremity soft tissue sarcoma
Yongsung Kim, Han‐Soo Kim, Hwan Seong Cho, Ilkyu Han
Journal of Surgical Oncology.2019; 120(2): 193. CrossRef
Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma
Elaine Johanna Limkin, Pierre Blanchard
The British Journal of Radiology.2019;[Epub] CrossRef
Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma
Wen Wen, Shi-Juan Mai, Huan-Xin Lin, Mei-Yin Zhang, Jia-Ling Huang, Xin Hua, Chao Lin, Zhi-Qing Long, Zi-Jian Lu, Xiao-Qing Sun, Sai-Lan Liu, Qi Yang, Qian Zhu, Hui-Yun Wang, Ling Guo
Journal of Translational Medicine.2019;[Epub] CrossRef
Utility of Serum EB Virus Zta Antibody in the Diagnostic of Nasopharyngeal Carcinoma: Evidences From 2,126 Cases and 15,644 Controls
Guangying Zhang, Zhanzhan Li, Qin Zhou
Frontiers in Oncology.2019;[Epub] CrossRef
Impact of age on survival of locoregional nasopharyngeal carcinoma: An analysis of the Surveillance, Epidemiology, and End Results program database, 2004‐2013
S.‐J. Huang, Y.‐Y. Tang, H.‐M. Liu, G.‐X. Tan, X. Wang, H. Zhang, F. Yang, S. Yang
Clinical Otolaryngology.2018; 43(5): 1209. CrossRef
Conditional survival in patients with gallbladder cancer
Yi-Jun Kim, Kyubo Kim
Chinese Journal of Cancer.2017;[Epub] CrossRef

24,225 View
319 Download
29 Web of Science
27 Crossref

The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients: Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Ming-Yuan Chen, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Jing Tan, Shuai Chen, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, Hai-Qiang Mai; Cancer Res Treat. 2018;50(1):19-29. Published online April 5, 2017; DOI: https://doi.org/10.4143/crt.2016.595

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to evaluate the prognostic value of treatment-related lymphopenia in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
A total of 413 consecutive stage II-IVb NPC patients treated with concurrent chemoradiotherapy (CCRT) were enrolled. The overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) were calculated with the Kaplan-Meier method, and differences were compared using the log-rank test.
Results
A minimum (mini)–absolute lymphocyte counts (ALC) of < 390 cells/μL or ALC after 3 months of CCRT (post3m-ALC) < 705 cells/μL was significantly associated with worse outcome than mini-ALC ≥ 390 cells/μL (OS, p=0.002; PFS, p=0.005; DMFS, p=0.004) or post3m-ALC ≥ 705 cells/μL (OS, p < 0.001; PFS, p < 0.001; DMFS, p=0.001). Patients with lymphopenia (mini-ALC < 390 cells/μL and post3m-ALC < 705 cells/μL) had a worse prognosis than those without lymphopenia (mini-ALC ≥ 390 cells/μL and post3m-ALC ≥ 705 cells/μL) (OS, p < 0.001; PFS, p < 0.001; DMFS, p < 0.001). Multivariate analysis revealed that post3m-ALC was an independent prognostic factor for OS (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.12 to 2.78; p=0.015), PFS (HR, 1.86; 95% CI, 1.23 to 2.82; p=0.003), and DMFS (HR, 1.87; 95% CI, 1.13 to 3.08; p=0.014). Multivariate analysis also revealed that patients with lymphopenia had a high risk of death (HR, 3.79; 95% CI, 1.75 to 8.19; p=0.001), disease progression (HR, 2.93; 95% CI, 1.59 to 5.41; p=0.001), and distant metastasis (HR, 3.89; 95% CI, 1.67 to 9.10; p=0.002). Multivariate analysis performed with time dependent Cox regression demonstrated ALC was an independent prognostic factor for OS (HR, 0.995; 95% CI, 0.991 to 0.999; p=0.025) and PFS (HR, 0.993; 95% CI, 0.988 to 0.998; p=0.006).
Conclusion
Treatment-related lymphopenia was a poor prognostic factor in NPC patients.

Citations

Citations to this article as recorded by

Impact of circulating lymphocyte kinetics following radiotherapy on patient survival: A model-based meta-analysis
Thao-Nguyen Pham, Julie Coupey, Juliette Thariat, Samuel Valable
Computers in Biology and Medicine.2025; 186: 109702. CrossRef
Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma
Jianyun Jiang, Ruiping Zhai, Fangfang Kong, Chengrun Du, Hongmei Ying
European Archives of Oto-Rhino-Laryngology.2024; 281(1): 181. CrossRef
Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study
Wei-Wei Zhang, Jia-Yi Lin, Gao-Yuan Wang, Cheng-Long Huang, Ling-Long Tang, Yan-Ping Mao, Guan-Qun Zhou, Li-Zhi Liu, Li Tian, Ji-Bin Li, Jun Ma, Rui Guo
Radiotherapy and Oncology.2024; 194: 110189. CrossRef
Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial
Cheng-Long Huang, Ning Zhang, Wei Jiang, Fang-Yun Xie, Xiao-Qing Pei, Shao Hui Huang, Xue-Yan Wang, Yan-Ping Mao, Kun-Peng Li, Qing Liu, Ji-Bin Li, Shao-Qiang Liang, Guan-Jie Qin, Wei-Han Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Lei Chen, Ling-Long Tang
Journal of Clinical Oncology.2024; 42(17): 2021. CrossRef
Immunological effects of radiopharmaceutical therapy
Amanda G. Shea, Malick Bio Idrissou, Ana Isabel Torres, Tessa Chen, Reiner Hernandez, Zachary S. Morris, Quaovi H. Sodji
Frontiers in Nuclear Medicine.2024;[Epub] CrossRef
Current Status and Future Directions of Proton Therapy for Head and Neck Carcinoma
Sara Lillo, Alfredo Mirandola, Alessandro Vai, Anna Maria Camarda, Sara Ronchi, Maria Bonora, Rossana Ingargiola, Barbara Vischioni, Ester Orlandi
Cancers.2024; 16(11): 2085. CrossRef
Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis
Ke-gui Weng, Hai-ke Lei, De-Song Shen, Ying Wang, Xiao-Dong Zhu
Cancer Management and Research.2024; Volume 16: 603. CrossRef
A prognostic nomogram for patients with III–IV nasopharyngeal carcinoma based on dynamic changes in the inflammatory and nutrition index
Guangyi Cheng, Shiwang Yuan, Jiang Wang, Sijia Deng, Yang Wu, Yuyan Wang, Yu Shen, Liantao Li
Clinical and Translational Oncology.2024;[Epub] CrossRef
Impact of Radiation Dose to Circulating Immune Cells on Tumor Control and Survival in Esophageal Cancer
Shang Cai, Yawen Fan, Qi Guo, Yanze Sun, Peifeng Zhao, Ye Tian, Qiuhong Fan
Cancer Biotherapy and Radiopharmaceuticals.2023; 38(6): 380. CrossRef
Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers
Yasmine El Houat, Christophe Massard, Veronique Quillien, Renaud de Crevoisier, Joël Castelli
Advances in Radiation Oncology.2023; 8(2): 101038. CrossRef
The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: A systematic review and meta-analysis
Li Wang, Xianfei Qin, Yu Zhang, Shouyu Xue, Xicheng Song
Frontiers in Oncology.2023;[Epub] CrossRef
Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy
Ji Min Yun, Man Ki Chung, Chung Hwan Baek, Young Ik Son, Myung Ju Ahn, Dongryul Oh, Ki Won Kim, Yoon Kyoung So
Cancers.2023; 15(4): 1248. CrossRef
Analysis of risk characteristics for metachronous metastasis in different period of nasopharyngeal carcinoma
Zhaodong Fei, Huiling Hong, Ting Xu, Yiying Xu, Jiawei Chen, Xiufang Qiu, Jianming Ding, Ye Feng, Chaoxiong Huang, Li Li, Mengying Li, Chuanben Chen
BMC Cancer.2023;[Epub] CrossRef
Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma
Jianjian Qiu, Hancui Lin, Dongmei Ke, Yilin Yu, Jiaying Xu, Hejin Qiu, Qunhao Zheng, Hui Li, Hongying Zheng, Lingyun Liu, Zhiping Wang, Qiwei Yao, Jiancheng Li
Frontiers in Immunology.2023;[Epub] CrossRef
Prognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma
Rema Shah, Christina Liu, Hemali P. Shah, Benjamin L. Judson
Laryngoscope Investigative Otolaryngology.2023; 8(4): 870. CrossRef
Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation
Jinliang Zhang, Li Yang, Hui Li, Jeff W. Chan, Eric K.W. Lee, Min Liu, Lingyu Ma, Qin Liu, Jian-Yue Jin, Pingfu Fu, Zhiyuan Xu, Feng-Ming (Spring) Kong
Advances in Radiation Oncology.2023; 8(6): 101260. CrossRef
Lymphopénie radio-induite : les lymphocytes comme nouvel organe à risque
P.A. Laurent, É. Deutsch
Cancer/Radiothérapie.2023; 27(6-7): 511. CrossRef
Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape
Yuanyuan Ma, Chang Guo, Xijun Wang, Xundong Wei, Jie Ma
Journal of Experimental & Clinical Cancer Research.2023;[Epub] CrossRef
CT-based dosiomics and radiomics model predicts radiation-induced lymphopenia in nasopharyngeal carcinoma patients
Qingfang Huang, Chao Yang, Jinmeng Pang, Biao Zeng, Pei Yang, Rongrong Zhou, Haijun Wu, Liangfang Shen, Rong Zhang, Fan Lou, Yi Jin, Albert Abdilim, Hekun Jin, Zijian Zhang, Xiaoxue Xie
Frontiers in Oncology.2023;[Epub] CrossRef
Developing the POTOMAC Model: A Novel Prediction Model to Study the Impact of Lymphopenia Kinetics on Survival Outcomes in Head and Neck Cancer Via an Ensemble Tree-Based Machine Learning Approach
Carmen Kut, Doug Midthune, Emerson Lee, Peyton Fair, Tia Cheunkarndee, Todd McNutt, Theodore DeWeese, Carole Fakhry, Victor Kipnis, Harry Quon
JCO Clinical Cancer Informatics.2023;[Epub] CrossRef
Preoperative prognostic nutritional index predicts prognosis of patients with oral cavity cancer
Ku‐Hao Fang, Sheng‐Wei Chang, Yi‐Chan Lee, Ethan I. Huang, Chia‐Hsuan Lai, Geng‐He Chang, Ming‐Shao Tsai, Cheng‐Ming Hsu, Yao‐Te Tsai
Oral Diseases.2022; 28(7): 1816. CrossRef
A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma
Yajing Zhang, Yujie Zhu, Jiaqi Wang, Yi Xu, Zekun Wang, Yang Liu, Xuebing Di, Lin Feng, Ye Zhang
Cancer Immunology, Immunotherapy.2022; 71(3): 675. CrossRef
Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein‐Barr virus DNA
Li‐Ting Liu, Yu‐Jing Liang, Shan‐Shan Guo, Yao Xie, Guo‐Dong Jia, Dong‐Xiang Wen, Lin‐Quan Tang, Qiu‐Yan Chen, Hai‐Qiang Mai
Head & Neck.2022; 44(1): 34. CrossRef
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis
Chengrun Du, Mengshan Ni, Jianyun Jiang, Fangfang Kong, Ruiping Zhai, Yingchen Lv, Chaosu Hu, Hongmei Ying
European Archives of Oto-Rhino-Laryngology.2022; 279(8): 3947. CrossRef
The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis
Dongjun Dai, Qiaoying Tian, Yongjie Shui, Jinfan Li, Qichun Wei
Radiotherapy and Oncology.2022; 168: 28. CrossRef
Systematic construction and external validation of an immune‐related prognostic model for nasopharyngeal carcinoma
Weiqun Lin, Di Cao, Annan Dong, Shaobo Liang, Yongyi Zhao, Cuibing Liu, Yinghua Yan, Xiaoliu Luo, Lizhi Liu, Xinchen Zeng, Qiaowen Ou
Head & Neck.2022; 44(5): 1086. CrossRef
Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer
Fang Chen, Jian-Yue Jin, Timothy S.K. Hui, Haiman Jing, Hong Zhang, Yaqing Nong, Ying Han, Weili Wang, Lingyu Ma, Fan Yi, Qingqing Chen, Yongsheng Zhang, Pingfu Fu, Li Yang, Zhiyuan Xu, Feng-Ming Spring Kong
Frontiers in Oncology.2022;[Epub] CrossRef
RuleFit-Based Nomogram Using Inflammatory Indicators for Predicting Survival in Nasopharyngeal Carcinoma, a Bi-Center Study
Chao Luo, Shuqi Li, Qin Zhao, Qiaowen Ou, Wenjie Huang, Guangying Ruan, Shaobo Liang, Lizhi Liu, Yu Zhang, Haojiang Li
Journal of Inflammation Research.2022; Volume 15: 4803. CrossRef
Head and neck cancers volume reduction: should we reduce our prophylactic node radiation to spare the antitumor immune response?
Y. El Houat, L. Bouvier, M. Baty, X. Palard-Novello, Y. Pointreau, R. de Crevoisier, J. Castelli
Cancer/Radiothérapie.2022; 26(6-7): 916. CrossRef
Establishment of a prognostic nomogram for patients with locoregionally advanced nasopharyngeal carcinoma incorporating clinical characteristics and dynamic changes in hematological and inflammatory markers
Qin Liu, Lingyu Ma, Huangrong Ma, Li Yang, Zhiyuan Xu
Frontiers in Oncology.2022;[Epub] CrossRef
The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers
Ava Saidian, Isabella Dolendo, Andrew Sharabi, Tyler F. Stewart, Brent Rose, Rana R. McKay, Aditya Bagrodia, Amirali Salmasi
Cancers.2022; 15(1): 127. CrossRef
Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients
FangJie Liu, YingJia Wu, JianHui Shao, Bo Qiu, SuPing Guo, QiaoTing Luo, JinYu Guo, DaQuan Wang, Chu Chu, Rui Zhou, NaiBin Chen, XinLei Ai, Hui Liu
Frontiers in Oncology.2022;[Epub] CrossRef
Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
Mame Daro-Faye, Wassim Kassouf, Luis Souhami, Gautier Marcq, Fabio Cury, Tamim Niazi, Paul Sargos
World Journal of Urology.2021; 39(5): 1331. CrossRef
Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes
Hui Xu, Maosheng Lin, Yingying Hu, Li Zhang, Qiaoqiao Li, Jinhan Zhu, Shi Wang, Mian Xi
The Oncologist.2021; 26(3): e425. CrossRef
Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy
Michael I. Koukourakis, Alexandra Giatromanolaki
Critical Reviews in Oncology/Hematology.2021; 159: 103226. CrossRef
Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival
Cynthia Terrones-Campos, Bruno Ledergerber, Ivan Richter Vogelius, Marie Helleberg, Lena Specht, Jens Lundgren
Radiotherapy and Oncology.2021; 158: 175. CrossRef
Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study
Wang Jing, Yufei Liu, Hui Zhu, James Welsh, Saumil Gandhi, Melenda Jeter, Quynh Nguyen, Aileen B. Chen, Michael O'Reilly, Zhongxing Liao, Joe Y. Chang, Percy Lee, Steven H. Lin
Clinical and Translational Radiation Oncology.2021; 28: 54. CrossRef
Prognostic value of neutrophils for patients with nasopharyngeal carcinoma
Lisha Chen, Mengying Li, Ting Xu, Xiufang Qiu, Chuanben Chen
Laryngoscope Investigative Otolaryngology.2021; 6(2): 219. CrossRef
The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis
Pim J.J. Damen, Tiuri E. Kroese, Richard van Hillegersberg, Ewoud Schuit, Max Peters, Joost J.C. Verhoeff, Steven H. Lin, Peter S.N. van Rossum
International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 936. CrossRef
Prognostic Significance of Circulating Lymphocyte Subsets Before Treatment in Patients with Nasopharyngeal Carcinoma
De-Song Shen, Chang Yan, Yu Liang, Kai-Hua Chen, Xiao-Dong Zhu
Cancer Management and Research.2021; Volume 13: 8109. CrossRef
Proton therapy for locally advanced non-small cell lung cancer
Olsi Gjyshi, Zhongxing Liao
The British Journal of Radiology.2020;[Epub] CrossRef
Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis
Jiawen Zhao, Weijia Huang, Yongxian Wu, Yihuan Luo, Bo Wu, Jiwen Cheng, Junqiang Chen, Deyun Liu, Chengyang Li
Cancer Cell International.2020;[Epub] CrossRef
Prognosis and Risk Factors of Radiation-Induced Lymphopenia in Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy
Qianqian Zhao, Tingting Li, Gang Chen, Zhaochong Zeng, Jian He
Frontiers in Oncology.2020;[Epub] CrossRef
Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram
Peter S.N. van Rossum, Wei Deng, David M. Routman, Amy Y. Liu, Cai Xu, Yutaka Shiraishi, Max Peters, Kenneth W. Merrell, Christopher L. Hallemeier, Radhe Mohan, Steven H. Lin
Practical Radiation Oncology.2020; 10(1): e16. CrossRef
Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count
Xiaoxue Xie, Shenglan Gong, Hekun Jin, Pei Yang, Ting Xu, Yilong Cai, Chengxian Guo, Rong Zhang, Fan Lou, Wenjuan Yang, Hui Wang
Radiation Oncology.2020;[Epub] CrossRef
Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer
Yasunori Yoshino, Ayumi Taguchi, Maki Takao, Tomoko Kashiyama, Akiko Furusawa, Masaya Uno, Satoshi Okada, Nao Kino, Toshiharu Yasugi
International Journal of Clinical Oncology.2019; 24(4): 428. CrossRef
Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
Michael D. Schad, Sunil W. Dutta, Donald M. Muller, Krishni Wijesooriya, Timothy N. Showalter
Advances in Radiation Oncology.2019; 4(2): 323. CrossRef
Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era
Hwa Kyung Byun, Nalee Kim, Hong In Yoon, Seok-Gu Kang, Se Hoon Kim, Jaeho Cho, Jong Geol Baek, Jong Hee Chang, Chang-Ok Suh
Radiation Oncology.2019;[Epub] CrossRef
Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma
Hwa Kyung Byun, Nalee Kim, Sangjoon Park, Jinsil Seong
Strahlentherapie und Onkologie.2019; 195(11): 1007. CrossRef
Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy
Qiaoqiao Li, Sha Zhou, Shiliang Liu, Songran Liu, Hong Yang, Lei Zhao, Mengzhong Liu, Yonghong Hu, Mian Xi
Annals of Surgical Oncology.2019; 26(9): 2882. CrossRef
Assessing the interactions between radiotherapy and antitumour immunity
Clemens Grassberger, Susannah G. Ellsworth, Moses Q. Wilks, Florence K. Keane, Jay S. Loeffler
Nature Reviews Clinical Oncology.2019; 16(12): 729. CrossRef
Overview of Hematopoietic Stem Cells in Systemic Cancer Treatment, Aging, Pregnancy, and Radiation Hormesis
Aleksei N. Shoutko
Advances in Molecular Imaging.2019; 09(02): 19. CrossRef
Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma
Sangjoon Park, Hwa Kyung Byun, Jinsil Seong
Liver Cancer.2019; 8(6): 468. CrossRef
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
Cheng Xu, Shi-Ping Yang, Yuan Zhang, Ling-Long Tang, Guan-Qun Zhou, Xu Liu, Yan-Ping Mao, Rui Guo, Wen-Fei Li, Lei Chen, Ai-Hua Lin, Ying Sun, Jun Ma
Cancer Research and Treatment.2018; 50(3): 777. CrossRef
Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors
Susannah G. Ellsworth
Advances in Radiation Oncology.2018; 3(4): 512. CrossRef
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
Anne Rodallec, Guillaume Sicard, Raphaelle Fanciullino, Sébastien Benzekry, Bruno Lacarelle, Gerard Milano, Joseph Ciccolini
Expert Opinion on Drug Metabolism & Toxicology.2018; : 1. CrossRef

12,152 View
360 Download
61 Web of Science
56 Crossref

First
Prev
Page of 1
Next
Last

Search